Misplaced Pages

Progesterone

Clinical data
Trade names	Prometrium, Utrogestan, Endometrin, others
Other names	P4; Pregnenedione; Pregn-4-ene-3,20-dione
AHFS/Drugs.com	Monograph
MedlinePlus	a604017
Routes of administration	By mouth, sublingual, topical, vaginal, rectal, intramuscular, subcutaneous, intrauterine
Drug class	Progestogen; Antimineralocorticoid; Neurosteroid
ATC code	G03DA04 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	Oral: <2.4% Vaginal (micronized insert): 4–8%
Protein binding	98–99%: • Albumin: 80% • CBGTooltip Corticosteroid-binding globulin: 18% • SHBGTooltip Sex hormone-binding globulin: <1% • Free: 1–2%
Metabolism	Mainly liver: • 5α- and 5β-reductase • 3α-Tooltip 3α-Hydroxysteroid dehydrogenase and 3β-HSDTooltip 3β-Hydroxysteroid dehydrogenase • 20α-Tooltip 20α-Hydroxysteroid dehydrogenase and 20β-HSDTooltip 20β-Hydroxysteroid dehydrogenase • Conjugation • 17α-Hydroxylase • 21-Hydroxylase • CYPsTooltip CYP (e.g., CYP3A4)
Metabolites	• Dihydroprogesterones • Pregnanolones • Pregnanediols • 20α-Hydroxyprogesterone • 17α-Hydroxyprogesterone • Pregnanetriols • 11-Deoxycorticosterone (and glucuronide/sulfate conjugates)
Elimination half-life	• Oral: 5 hours (with food) * Sublingual: 6–7 hours • Vaginal: 14–50 hours • Topical: 30–40 hours • IM: 20–28 hours • SC: 13–18 hours • IVTooltip Intravenous injection: 3–90 minutes
Excretion	Bile and urine
Identifiers
IUPAC name (8S,9S,10R,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopentaphenanthren-3-one
CAS Number	57-83-0
PubChem CID	5994
IUPHAR/BPS	2377
DrugBank	DB00396
ChemSpider	5773
UNII	4G7DS2Q64Y
KEGG	D00066
ChEBI	CHEBI:17026
ChEMBL	ChEMBL103
Chemical and physical data
Formula	C21H30O2
Molar mass	314.469 g·mol
3D model (JSmol)	Interactive image
Specific rotation	D = +172 to +182° (2% in dioxane, β-form)
Melting point	126 °C (259 °F)
SMILES CC(=O)1CC21(CC32CCC4=CC(=O)CC34C)C
InChI InChI=InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1 Key:RJKFOVLPORLFTN-LEKSSAKUSA-N
(verify)

Progesterone (P4), sold under the brand name Prometrium among others, is a medication and naturally occurring steroid hormone. It is a progestogen and is used in combination with estrogens mainly in hormone therapy for menopausal symptoms and low sex hormone levels in women. It is also used in women to support pregnancy and fertility and to treat gynecological disorders. Progesterone can be taken by mouth, vaginally, and by injection into muscle or fat, among other routes. A progesterone vaginal ring and progesterone intrauterine device used for birth control also exist in some areas of the world.

Progesterone is well tolerated and often produces few or no side effects. However, a number of side effects are possible, for instance mood changes. If progesterone is taken by mouth or at high doses, certain central side effects including sedation, sleepiness, and cognitive impairment can also occur. The medication is a naturally occurring progestogen and hence is an agonist of the progesterone receptor (PR), the biological target of progestogens like endogenous progesterone. It opposes the effects of estrogens in various parts of the body like the uterus and also blocks the effects of the hormone aldosterone. In addition, progesterone has neurosteroid effects in the brain.

Progesterone was first isolated in pure form in 1934. It first became available as a medication later that year. Oral micronized progesterone (OMP), which allowed progesterone to be taken by mouth, was introduced in 1980. A large number of synthetic progestogens, or progestins, have been derived from progesterone and are used as medications as well. Examples include medroxyprogesterone acetate and norethisterone. In 2022, it was the 125th most commonly prescribed medication in the United States, with more than 5 million prescriptions.

Medical uses

Menopause

Progesterone is used in combination with an estrogen as a component of menopausal hormone therapy for the treatment of menopausal symptoms in peri- and postmenopausal women. It is used specifically to provide endometrial protection against unopposed estrogen-induced endometrial hyperplasia and cancer in women with intact uteruses. A 2016 systematic review of endometrial protection with progesterone recommended 100 mg/day continuous oral progesterone, 200 mg/day cyclic oral progesterone, 45 to 100 mg/day cyclic vaginal progesterone, and 100 mg alternate-day vaginal progesterone. Twice-weekly 100 mg vaginal progesterone was also recommended, but more research is needed on this dose and endometrial monitoring may be advised. Transdermal progesterone was not recommended for endometrial protection.

The REPLENISH trial was the first adequately powered study to show that continuous 100 mg/day oral progesterone with food provides adequate endometrial protection. Cyclic 200 mg/day oral progesterone has also been found to be effective in the prevention of endometrial hyperplasia, for instance in the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. However, the PEPI trial was not adequately powered to fully quantify endometrial hyperplasia or cancer risk. No adequately powered studies have assessed endometrial protection with vaginal progesterone. In any case, the Early versus Late Intervention Trial with Estradiol (ELITE) found that cyclic 45 mg/day vaginal progesterone gel showed no significant difference from placebo in endometrial cancer rates. Due to the vaginal first-pass effect, low doses of vaginal progesterone may allow for adequate endometrial protection. Although not sufficiently powered, various other smaller studies have also found endometrial protection with oral or vaginal progesterone. There is inadequate evidence for endometrial protection with transdermal progesterone cream.

Oral progesterone has been found to significantly reduce hot flashes relative to placebo. The combination of an estrogen and oral progesterone likewise reduces hot flashes. Estrogen plus oral progesterone has been found to significantly improve quality of life. The combination of an estrogen and 100 to 300 mg/day oral progesterone has been found to improve sleep outcomes. Moreover, sleep was improved to a significantly better extent than estrogen plus medroxyprogesterone acetate. This may be attributable to the sedative neurosteroid effects of progesterone. Reduction of hot flashes may also help to improve sleep outcomes. Based on animal research, progesterone may be involved in sexual function in women. However, very limited clinical research suggests that progesterone does not improve sexual desire or function in women.

The combination of an estrogen and oral progesterone has been found to improve bone mineral density (BMD) to a similar extent as an estrogen plus medroxyprogesterone acetate. Progestogens, including progesterone, may have beneficial effects on bone independent of those of estrogens, although more research is required to confirm this notion. The combination of an estrogen and oral or vaginal progesterone has been found to improve cardiovascular health in women in early menopause but not in women in late menopause. Estrogen therapy has a favorable influence on the blood lipid profile, which may translate to improved cardiovascular health. The addition of oral or vaginal progesterone has neutral or beneficial effects on these changes. This is in contrast to various progestins, which are known to antagonize the beneficial effects of estrogens on blood lipids. Progesterone, both alone and in combination with an estrogen, has been found to have beneficial effects on skin and to slow the rate of skin aging in postmenopausal women.

In the French E3N-EPIC observational study, the risk of diabetes was significantly lower in women on menopausal hormone therapy, including with the combination of an oral or transdermal estrogen and oral progesterone or a progestin.

Transgender women

Progesterone is used as a component of feminizing hormone therapy for transgender women in combination with estrogens and antiandrogens. However, the addition of progestogens to HRT for transgender women is controversial and their role is unclear. Some patients and clinicians believe anecdotally that progesterone may enhance breast development, improve mood, regulate sleep, and increase sex drive. However, there is a lack of evidence from well-designed studies to support these notions at present. In addition, progestogens can produce undesirable side effects, although bioidentical progesterone may be safer and better tolerated than synthetic progestogens like medroxyprogesterone acetate.

Because some believe that progestogens are necessary for full breast development, progesterone is sometimes used in transgender women with the intention of enhancing breast development. However, a 2014 review concluded the following on the topic of progesterone for enhancing breast development in transgender women:

Our knowledge concerning the natural history and effects of different cross-sex hormone therapies on breast development in women is extremely sparse and based on low quality of evidence. Current evidence does not provide evidence that progestogens enhance breast development in women. Neither do they prove the absence of such an effect. This prevents us from drawing any firm conclusion at this moment and demonstrates the need for further research to clarify these important clinical questions.

Data on menstruating women shows there is no correlation between water retention, and levels of progesterone or estrogen. Despite this, some theorise progesterone might cause temporary breast enlargement due to local fluid retention, and may thus give a misleading appearance of breast growth. Aside from a hypothetical involvement in breast development, progestogens are not otherwise known to be involved in physical feminization.

Pregnancy support

Vaginally dosed progesterone is being investigated as potentially beneficial in preventing preterm birth in women at risk for preterm birth. The initial study by Fonseca suggested that vaginal progesterone could prevent preterm birth in women with a history of preterm birth. According to a recent study, women with a short cervix that received hormonal treatment with a progesterone gel had their risk of prematurely giving birth reduced. The hormone treatment was administered vaginally every day during the second half of a pregnancy. A subsequent and larger study showed that vaginal progesterone was no better than placebo in preventing recurrent preterm birth in women with a history of a previous preterm birth, but a planned secondary analysis of the data in this trial showed that women with a short cervix at baseline in the trial had benefit in two ways: a reduction in births less than 32 weeks and a reduction in both the frequency and the time their babies were in intensive care.

In another trial, vaginal progesterone was shown to be better than placebo in reducing preterm birth prior to 34 weeks in women with an extremely short cervix at baseline. An editorial by Roberto Romero discusses the role of sonographic cervical length in identifying patients who may benefit from progesterone treatment. A meta-analysis published in 2011 found that vaginal progesterone cut the risk of premature births by 42 percent in women with short cervixes. The meta-analysis, which pooled published results of five large clinical trials, also found that the treatment cut the rate of breathing problems and reduced the need for placing a baby on a ventilator.

Fertility support

Progesterone is used for luteal support in assisted reproductive technology (ART) cycles such as in vitro fertilization (IVF). It is also used to correct luteal phase deficiency to prepare the endometrium for implantation in infertility therapy and is used to support early pregnancy.

Birth control

A progesterone vaginal ring is available for birth control when breastfeeding in a number of areas of the world. An intrauterine device containing progesterone has also been marketed under the brand name Progestasert for birth control, including previously in the United States.

Gynecological disorders

Progesterone is used to control persistent anovulatory bleeding.

Other uses

Progesterone is of unclear benefit for the reversal of mifepristone-induced abortion. Evidence is insufficient to support use in traumatic brain injury.

Progesterone has been used as a topical medication applied to the scalp to treat female and male pattern hair loss. Variable effectiveness has been reported, but overall its effectiveness for this indication in both sexes has been poor.

Breast pain

Progesterone is approved under the brand name Progestogel as a 1% topical gel for local application to the breasts to treat breast pain in certain countries. It is not approved for systemic therapy. It has been found in clinical studies to inhibit estrogen-induced proliferation of breast epithelial cells and to abolish breast pain and tenderness in women with the condition. However, in one small study in women with cyclic breast pain it was ineffective. Vaginal progesterone has also been found to be effective in the treatment of breast pain and tenderness.

Premenstrual syndrome

Historically, progesterone has been widely used in the treatment of premenstrual syndrome. A 2012 Cochrane review found insufficient evidence for or against the effectiveness of progesterone for this indication. Another review of 10 studies found that progesterone was not effective for this condition, although it stated that insufficient evidence is available currently to make a definitive statement on progesterone in premenstrual syndrome.

Catamenial epilepsy

Progesterone can be used to treat catamenial epilepsy by supplementation during certain periods of the menstrual cycle.

Available forms

Progesterone is available in a variety of different forms, including oral capsules; sublingual tablets; vaginal capsules, tablets, gels, suppositories, and rings; rectal suppositories; oil solutions for intramuscular injection; and aqueous solutions for subcutaneous injection. A 1% topical progesterone gel is approved for local application to the breasts to treat breast pain, but is not indicated for systemic therapy. Progesterone was previously available as an intrauterine device for use in hormonal contraception, but this formulation was discontinued. Progesterone is also limitedly available in combination with estrogens such as estradiol and estradiol benzoate for use by intramuscular injection.

In addition to approved pharmaceutical products, progesterone is available in unregulated custom compounded and over-the-counter formulations like systemic transdermal creams and other preparations. The systemic efficacy of transdermal progesterone is controversial and has not been demonstrated.

Contraindications

Contraindications of progesterone include hypersensitivity to progesterone or progestogens, prevention of cardiovascular disease (a Black Box warning), thrombophlebitis, thromboembolic disorder, cerebral hemorrhage, impaired liver function or disease, breast cancer, reproductive organ cancers, undiagnosed vaginal bleeding, missed menstruations, miscarriage, or a history of these conditions. Progesterone should be used with caution in people with conditions that may be adversely affected by fluid retention such as epilepsy, migraine headaches, asthma, cardiac dysfunction, and renal dysfunction. It should also be used with caution in patients with anemia, diabetes mellitus, a history of depression, previous ectopic pregnancy, and unresolved abnormal Pap smear. Use of progesterone is not recommended during pregnancy and breastfeeding. However, the medication has been deemed usually safe in breastfeeding by the American Academy of Pediatrics, but should not be used during the first four months of pregnancy. Some progesterone formulations contain benzyl alcohol, and this may cause a potentially fatal "gasping syndrome" if given to premature infants.

Side effects

Progesterone is well tolerated, and many clinical studies have reported no side effects. Side effects of progesterone may include abdominal cramps, back pain, breast tenderness, constipation, nausea, dizziness, edema, vaginal bleeding, hypotension, fatigue, dysphoria, depression, and irritability, among others. Central nervous system depression, such as sedation and cognitive/memory impairment, can also occur.

Vaginal progesterone may be associated with vaginal irritation, itchiness, and discharge, decreased libido, painful sexual intercourse, vaginal bleeding or spotting in association with cramps, and local warmth or a "feeling of coolness" without discharge. Intramuscular injection may cause mild-to-moderate pain at the site of injection. High intramuscular doses of progesterone have been associated with increased body temperature, which may be alleviated with paracetamol treatment.

Progesterone lacks undesirable off-target hormonal activity, in contrast to various progestins. As a result, it is not associated with androgenic, antiandrogenic, estrogenic, or glucocorticoid effects. Conversely, progesterone can still produce side effects related to its antimineralocorticoid and neurosteroid activity. Compared to the progestin medroxyprogesterone acetate, there are fewer reports of breast tenderness with progesterone. In addition, the magnitude and duration of vaginal bleeding with progesterone are reported to be lower than with medroxyprogesterone acetate.

Central depression

Progesterone can produce central nervous system depression as an adverse effect, particularly with oral administration or with high doses of progesterone. These side effects may include drowsiness, sedation, sleepiness, fatigue, sluggishness, reduced vigor, dizziness, lightheadedness, confusion, and cognitive, memory, and/or motor impairment. Limited available evidence has shown minimal or no adverse influence on cognition with oral progesterone (100–600 mg), vaginal progesterone (45 mg gel), or progesterone by intramuscular injection (25–200 mg). However, high doses of oral progesterone (300–1200 mg), vaginal progesterone (100–200 mg), and intramuscular progesterone (100–200 mg) have been found to result in dose-dependent fatigue, drowsiness, and decreased vigor. Moreover, high single doses of oral progesterone (1200 mg) produced significant cognitive and memory impairment. Intravenous infusion of high doses of progesterone (e.g., 500 mg) has been found to induce deep sleep in humans. Some individuals are more sensitive and can experience considerable sedative and hypnotic effects at lower doses of oral progesterone (e.g., 400 mg).

Sedation and cognitive and memory impairment with progesterone are attributable to its inhibitory neurosteroid metabolites. These metabolites occur to a greater extent with oral progesterone, and may be minimized by switching to a parenteral route. Progesterone can also be taken before bed to avoid these side effects and to help with sleep. The neurosteroid effects of progesterone are unique to progesterone and are not shared with progestins.

Breast cancer

Breast cell proliferation has been found to be significantly increased by the combination of an oral estrogen plus cyclic medroxyprogesterone acetate in postmenopausal women but not by the combination of transdermal estradiol plus oral progesterone. Studies of topical estradiol and progesterone applied to the breasts for 2 weeks have been found to result in highly pharmacological local levels of estradiol and progesterone. These studies have assessed breast proliferation markers and have found increased proliferation with estradiol alone, decreased proliferation with progesterone, and no change in proliferation with estradiol and progesterone combined. In the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial, the combination of estrogen and cyclic oral progesterone resulted in a higher mammographic breast density than estrogen alone (3.1% vs. 0.9%) but a non-significantly lower breast density than the combination of estrogen and cyclic or continuous medroxyprogesterone acetate (3.1% vs. 4.4–4.6%). Higher breast density is a strong known risk factor for breast cancer. Other studies have had mixed findings however. A 2018 systematic review reported that breast density with an estrogen plus oral progesterone was significantly increased in three studies and unchanged in two studies. Changes in breast density with progesterone appear to be less than with the compared progestins.

In large short-term observational studies, estrogen alone and the combination of estrogen and oral progesterone have generally not been associated with an increased risk of breast cancer. Conversely, the combination of estrogen and almost any progestin, such as medroxyprogesterone acetate or norethisterone acetate, has been associated with an increased risk of breast cancer. The only exception among progestins is dydrogesterone, which has shown similar risk to that of oral progesterone. Breast cancer risk with estrogen and progestin therapy is duration-dependent, with the risk being significantly greater with more than 5 years of exposure relative to less than 5 years. In contrast to shorter-term studies, the longer-term observations (>5 years) of the French E3N study showed significant associations of both estrogen plus oral progesterone and estrogen plus dydrogesterone with higher breast cancer risk, similarly to estrogen plus other progestogens. Oral progesterone has very low bioavailability and has relatively weak progestogenic effects. The delayed onset of breast cancer risk with estrogen plus oral progesterone is potentially consistent with a weak proliferative effect of oral progesterone on the breasts. As such, a longer duration of exposure may be necessary for a detectable increase in breast cancer risk to occur. In any case, the risk remains lower than that with most progestins. A 2018 systematic review of progesterone and breast cancer concluded that short-term use (<5 years) of an estrogen plus progesterone is not associated with a significant increase in risk of breast cancer but that long-term use (>5 years) is associated with greater risk. The conclusions for progesterone were the same in a 2019 meta-analysis of the worldwide epidemiological evidence by the Collaborative Group on Hormonal Factors in Breast Cancer (CGHFBC).

Most data on breast density changes and breast cancer risk are with oral progesterone. Data on breast safety with vaginal progesterone are scarce. The Early versus Late Intervention Trial with Estradiol (ELITE) was a randomized controlled trial of about 650 postmenopausal women who used estradiol and 45 mg/day cyclic vaginal progesterone. Incidence of breast cancer was reported as an adverse effect. The absolute incidences were 10 cases in the estradiol plus vaginal progesterone group and 8 cases in the control group. However, the study was not adequately powered for quantifying breast cancer risk.

Blood clots

Whereas the combination of estrogen and a progestin is associated with increased risk of venous thromboembolism (VTE) relative to estrogen alone, there is no difference in risk of VTE with the combination of estrogen and oral progesterone relative to estrogen alone. Hence, in contrast to progestins, oral progesterone added to estrogen does not appear to increase coagulation or VTE risk. The reason for the differences between progesterone and progestins in terms of VTE risk are unclear. However, they may be due to very low progesterone levels and relatively weak progestogenic effects produced by oral progesterone. In contrast to oral progesterone, non-oral progesterone—which can achieve much higher progesterone levels—has not been assessed in terms of VTE risk.

Overdose

Progesterone is likely to be relatively safe in overdose. Levels of progesterone during pregnancy are up to 100-fold higher than during normal menstrual cycling, although levels increase gradually over the course of pregnancy. Oral dosages of progesterone of as high as 3,600 mg/day have been assessed in clinical trials, with the main side effect being sedation. There is a case report of progesterone misuse with an oral dosage of 6,400 mg per day. Administration of as much as 500 mg progesterone by intravenous infusion in humans was uneventful in terms of toxicity, but did induce deep sleep, though the individuals were still able to be awakened with sufficient stimulation.

Interactions

There are several notable drug interactions with progesterone. Certain selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, paroxetine, and sertraline may increase the GABA_A receptor-related central depressant effects of progesterone by enhancing its conversion into 5α-dihydroprogesterone and allopregnanolone via activation of 3α-HSD. Progesterone potentiates the sedative effects of benzodiazepines and alcohol. Notably, there is a case report of progesterone abuse alone with very high doses. 5α-Reductase inhibitors such as finasteride and dutasteride inhibit the conversion of progesterone into the inhibitory neurosteroid allopregnanolone, and for this reason, may have the potential to reduce the sedative and related effects of progesterone.

Progesterone is a weak but significant agonist of the pregnane X receptor (PXR), and has been found to induce several hepatic cytochrome P450 enzymes, such as CYP3A4, especially when concentrations are high, such as with pregnancy range levels. As such, progesterone may have the potential to accelerate the metabolism of various medications.

Pharmacology

Pharmacodynamics

Progesterone is a progestogen, or an agonist of the nuclear progesterone receptors (PRs), the PR-A, PR-B, and PR-C. In addition, progesterone is an agonist of the membrane progesterone receptors (mPRs), including the mPRα, mPRβ, mPRγ, mPRδ, and mPRϵ. Aside from the PRs and mPRs, progesterone is a potent antimineralocorticoid, or antagonist of the mineralocorticoid receptor, the biological target of the mineralocorticoid aldosterone. In addition to its activity as a steroid hormone, progesterone is a neurosteroid. Among other neurosteroid activities, and via its active metabolites allopregnanolone and pregnanolone, progesterone is a potent positive allosteric modulator of the GABA_A receptor, the major signaling receptor of the inhibitory neurotransmitter γ-aminobutyric acid (GABA).

The PRs are expressed widely throughout the body, including in the uterus, cervix, vagina, fallopian tubes, breasts, fat, skin, pituitary gland, hypothalamus, and in other areas of the brain. In accordance, progesterone has numerous effects throughout the body. Among other effects, progesterone produces changes in the female reproductive system, the breasts, and the brain. Progesterone has functional antiestrogenic effects due to its progestogenic activity, including in the uterus, cervix, and vagina. The effects of progesterone may influence health in both positive and negative ways. In addition to the aforementioned effects, progesterone has antigonadotropic effects due to its progestogenic activity, and can inhibit ovulation and suppress gonadal sex hormone production.

The activities of progesterone besides those mediated by the PRs and mPRs are also of significance. Progesterone lowers blood pressure and reduces water and salt retention among other effects via its antimineralocorticoid activity. In addition, progesterone can produce sedative, hypnotic, anxiolytic, euphoric, amnestic, cognitive-impairing, motor-impairing, anticonvulsant, and even anesthetic effects via formation of sufficiently high concentrations of its neurosteroid metabolites and consequent GABA_A receptor potentiation in the brain.

There are differences between progesterones and progestins, such as medroxyprogesterone acetate and norethisterone, with implications for pharmacodynamics and pharmacokinetics, as well as for efficacy, tolerability, and safety.

Pharmacokinetics

The pharmacokinetics of progesterone are dependent on its route of administration. The medications is approved in the form of oil-filled capsules containing micronized progesterone for oral administration, termed oral micronized progesterone or OMP. It is also available in the form of vaginal or rectal suppositories or pessaries, topical creams and gels, oil solutions for intramuscular injection, and aqueous solutions for subcutaneous injection.

Routes of administration that progesterone has been used by include oral, intranasal, transdermal/topical, vaginal, rectal, intramuscular, subcutaneous, and intravenous injection. Vaginal progesterone is available in the form of progesterone capsules, tablets or inserts, gels, suppositories or pessaries, and rings.

The bioavailability of progesterone was commonly overestimated due to the immunoassay method of analysis failing to distinguish between progesterone itself and its metabolites. Newer methods have adjusted the oral bioavailbility estimate from 6.2 to 8.6% down to less than 2.4%.

Chemistry

Progesterone is a naturally occurring pregnane steroid and is also known as pregn-4-ene-3,20-dione. It has a double bond (4-ene) between the C4 and C5 positions and two ketone groups (3,20-dione), one at the C3 position and the other at the C20 position. Due to its pregnane core and C4(5) double bond, progesterone is often abbreviated as P4. It is contrasted with pregnenolone, which has a C5(6) double bond and is often abbreviated as P5.

Derivatives

A large number of progestins, or synthetic progestogens, have been derived from progesterone. They can be categorized into several structural groups, including derivatives of retroprogesterone, 17α-hydroxyprogesterone, 17α-methylprogesterone, and 19-norprogesterone, with a respective example from each group including dydrogesterone, medroxyprogesterone acetate, medrogestone, and promegestone. The progesterone ethers quingestrone (progesterone 3-cyclopentyl enol ether) and progesterone 3-acetyl enol ether are among the only examples that do not belong to any of these groups. Another major group of progestins, the 19-nortestosterone derivatives, exemplified by norethisterone (norethindrone) and levonorgestrel, are not derived from progesterone but rather from testosterone.

A variety of synthetic inhibitory neurosteroids have been derived from progesterone and its neurosteroid metabolites, allopregnanolone and pregnanolone. Examples include alfadolone, alfaxolone, ganaxolone, hydroxydione, minaxolone, and renanolone. In addition, C3 and C20 conjugates of progesterone, such as progesterone carboxymethyloxime (progesterone 3-(O-carboxymethyl)oxime; P4-3-CMO), P1-185 (progesterone 3-O-(L-valine)-E-oxime), EIDD-1723 (progesterone 20E-oxime] sodium salt), EIDD-036 (progesterone 20-oxime; P4-20-O), and VOLT-02 (chemical structure unreleased), have been developed as water-soluble prodrugs of progesterone and its neurosteroid metabolites.

Synthesis

Chemical syntheses of progesterone have been published.

History

Discovery and synthesis

The hormonal action of progesterone was discovered in 1929. Pure crystalline progesterone was isolated in 1934 and its chemical structure was determined. Later that year, chemical synthesis of progesterone was accomplished. Shortly following its chemical synthesis, progesterone began being tested clinically in women.

Injections and implants

In 1933 or 1934, Schering introduced progesterone in oil solution as a medication by intramuscular injection under the brand name Proluton. This was the first pharmaceutical formulation of progesterone to be marketed for medical use. It was initially a corpus luteum extract, becoming pure synthesized progesterone only subsequently. A clinical study of the formulation was published in 1933. Multiple formulations of progesterone in oil solution for intramuscular injection, under the brand names Proluton, Progestin, and Gestone, were available by 1936. A parenteral route was used because oral progesterone had very low activity and was thought to be inactive. Progesterone was initially very expensive due to the large doses required. However, with the start of steroid manufacturing from diosgenin in the 1940s, costs greatly decreased.

Subcutaneous pellet implants of progesterone were first studied in women in the late 1930s. They were the first long-acting progestogen formulation. Pellets were reported to be extruded out of the skin within a few weeks at high rates, even when implanted beneath the deep fascia, and also produced frequent inflammatory reactions at the site of implantation. In addition, they were absorbed too slowly and achieved unsatisfactorily low progesterone levels. Consequently, they were soon abandoned, in favor of other preparations such as aqueous suspensions. However, subcutaneous pellet implants of progesterone were later studied as a form of birth control in women in the 1980s and early 1990s, though no preparations were ultimately marketed.

Aqueous suspensions of progesterone crystals for intramuscular injection were first described in 1944. These preparations were on the market in the 1950s under a variety of brand names including Flavolutan, Luteosan, Lutocyclin M, and Lutren, among others. Aqueous suspensions of steroids were developed because they showed much longer durations than intramuscular injection of steroids in oil solution. However, local injection site reactions, which do not occur with oil solutions, have limited the clinical use of aqueous suspensions of progesterone and other steroids. Today, a preparation with the brand name Agolutin Depot remains on the market in the Czech Republic and Slovakia. A combined preparation of progesterone, estradiol benzoate, and lidocaine remains available with the brand name Clinomin Forte in Paraguay as well. In addition to aqueous suspensions, water-in-oil emulsions of steroids were studied by 1949, and long-acting emulsions of progesterone were introduced for use by intramuscular injection under the brand names Progestin and Di-Pro-Emulsion (with estradiol benzoate) by the 1950s. Due to lack of standardization of crystal sizes, crystalline suspensions of steroids had marked variations in effect. Emulsions were said to be even more unreliable.

Macrocrystalline aqueous suspensions of progesterone as well as microspheres of progesterone were investigated as potential progestogen-only injectable contraceptives and combined injectable contraceptives (with estradiol) by the late 1980s and early 1990s but were never marketed.

Aqueous solutions of water-insoluble steroids were first developed via association with colloid solubility enhancers in the 1940s. An aqueous solution of progesterone for use by intravenous injection was marketed by Schering AG under the brand name Primolut Intravenous by 1962. One of its intended uses was the treatment of threatened abortion, in which rapid-acting effect was desirable. An aqueous solution of progesterone complexed with cyclodextrin to increase its water solubility was introduced for use by once-daily subcutaneous injection in Europe under the brand name Prolutex in the mid-2010s.

In the 1950s, long-acting parenteral progestins such as hydroxyprogesterone caproate, medroxyprogesterone acetate, and norethisterone enanthate were developed and introduced for use by intramuscular injection. They lacked the need for frequent injections and the injection site reactions associated with progesterone by intramuscular injection and soon supplanted progesterone for parenteral therapy in most cases.

Oral and sublingual

The first study of oral progesterone in humans was published in 1949. It found that oral progesterone produced significant progestational effects in the endometrium in women. Prior to this study, animal research had suggested that oral progesterone was inactive, and for this reason, oral progesterone had never been evaluated in humans. A variety of other early studies of oral progesterone in humans were also published in the 1950s and 1960s. These studies generally reported oral progesterone to be only very weakly active. Oral non-micronized progesterone was introduced as a pharmaceutical medication around 1953, for instance as Cyclogesterin (1 mg estrogenic substances and 30 mg progesterone tablets) for menstrual disturbances by Upjohn, though it saw limited use. Another preparation, which contained progesterone alone, was Synderone (trademark registered by Chemical Specialties in 1952).

Sublingual progesterone in women was first studied in 1944 by Robert Greenblatt. Buccal progesterone tablets were marketed by Schering under the brand name Proluton Buccal Tablets by 1949. Sublingual progesterone tablets were marketed under the brand names Progesterone Lingusorbs and Progesterone Membrettes by 1951. A sublingual tablet formulation of progesterone has been approved under the brand name Luteina in Poland and Ukraine and remains marketed today.

Progesterone was the first progestogen that was found to inhibit ovulation, both in animals and in women. Injections of progesterone were first shown to inhibit ovulation in animals between 1937 and 1939. Inhibition of fertilization by administration of progesterone during the luteal phase was also demonstrated in animals between 1947 and 1949. Ovulation inhibition by progesterone in animals was subsequently re-confirmed and expanded on by Gregory Pincus and colleagues in 1953 and 1954. Findings on inhibition of ovulation by progesterone in women were first presented at the Fifth International Conference on Planned Parenthood in Tokyo, Japan in October 1955. Three different research groups presented their findings on this topic at the conference. They included Pincus (in conjunction with John Rock, who did not attend the conference); a nine-member Japanese group led by Masaomi Ishikawa; and the two-member team of Abraham Stone and Herbert Kupperman. The conference marked the beginning of a new era in the history of birth control. The results were subsequently published in scientific journals in 1956 in the case of Pincus and in 1957 in the case of Ishikawa and colleagues. Rock and Pincus also subsequently described findings from 1952 that "pseudopregnancy" therapy with a combination of high doses of diethylstilbestrol and oral progesterone prevented ovulation and pregnancy in women.

Unfortunately, the use of oral progesterone as a hormonal contraceptive was plagued by problems. These included the large and by extension expensive doses required, incomplete inhibition of ovulation even at high doses, and a frequent incidence of breakthrough bleeding. At the 1955 Tokyo conference, Pincus had also presented the first findings of ovulation inhibition by oral progestins in animals, specifically 19-nortestosterone derivatives like noretynodrel and norethisterone. These progestins were far more potent than progesterone, requiring much smaller doses orally. By December 1955, inhibition of ovulation by oral noretynodrel and norethisterone had been demonstrated in women. These findings as well as results in animals were published in 1956. Noretynodrel and norethisterone did not show the problems associated with oral progesterone—in the studies, they fully inhibited ovulation and did not produce menstruation-related side effects. Consequently, oral progesterone was abandoned as a hormonal contraceptive in women. The first birth control pills to be introduced were a noretynodrel-containing product in 1957 and a norethisterone-containing product in 1963, followed by numerous others containing a diversity of progestins. Progesterone itself has never been introduced for use in birth control pills.

More modern clinical studies of oral progesterone demonstrating elevated levels of progesterone and end-organ responses in women, specifically progestational endometrial changes, were published between 1980 and 1983. Up to this point, many clinicians and researchers apparently still thought that oral progesterone was inactive. It was not until almost half a century after the introduction of progesterone in medicine that a reasonably effective oral formulation of progesterone was marketed. Micronization of progesterone and suspension in oil-filled capsules, which allowed progesterone to be absorbed several-fold more efficiently by the oral route, was first studied in the late 1970s and described in the literature in 1982. This formulation, known as oral micronized progesterone (OMP), was then introduced for medical use under the brand name Utrogestan in France in 1982. Subsequently, oral micronized progesterone was introduced under the brand name Prometrium in the United States in 1998. By 1999, oral micronized progesterone had been marketed in more than 35 countries. In 2019, the first combination of oral estradiol and progesterone was introduced under the brand name Bijuva in the United States.

A sustained-release (SR) formulation of oral micronized progesterone, also known as "oral natural micronized progesterone sustained release" or "oral NMP SR", was marketed in India in 2012 under the brand name Gestofit SR. Many additional brand names followed. The preparation was originally developed in 1986 by a compounding pharmacy called Madison Pharmacy Associates in Madison, Wisconsin in the United States.

Vaginal, rectal, and uterine

Vaginal progesterone suppositories were first studied in women by Robert Greenblatt in 1954. Shortly thereafter, vaginal progesterone suppositories were introduced for medical use under the brand name Colprosterone in 1955. Rectal progesterone suppositories were first studied in men and women by Christian Hamburger in 1965. Vaginal and rectal progesterone suppositories were introduced for use under the brand name Cyclogest by 1976. Vaginal micronized progesterone gels and capsules were introduced for medical use under brand names such as Utrogestan and Crinone in the early 1990s. Progesterone was approved in the United States as a vaginal gel in 1997 and as a vaginal insert in 2007. A progesterone contraceptive vaginal ring known as Progering was first studied in women in 1985 and continued to be researched through the 1990s. It was approved for use as a contraceptive in lactating mothers in Latin America by 2004. A second progesterone vaginal ring known as Fertiring was developed as a progesterone supplement for use during assisted reproduction and was approved in Latin America by 2007.

Development of a progesterone-containing intrauterine device (IUD) for contraception began in the 1960s. Incorporation of progesterone into IUDs was initially studied to help reduce the risk of IUD expulsion. However, while addition of progesterone to IUDs showed no benefit on expulsion rates, it was unexpectedly found to induce endometrial atrophy. This led in 1976 to the development and introduction of Progestasert, a progesterone-containing product and the first progestogen-containing IUD. Unfortunately, the product had various problems that limited its use. These included a short duration of efficacy of only one year, a high cost, a relatively high 2.9% failure rate, a lack of protection against ectopic pregnancy, and difficult and sometimes painful insertions that could necessitate use of a local anesthetic or analgesic. As a result of these issues, Progestasert never became widely used, and was discontinued in 2001. It was used mostly in the United States and France while it was marketed.

Transdermal and topical

A topical gel formulation of progesterone, for direct application to the breasts as a local therapy for breast disorders such as breast pain, was introduced under the brand name Progestogel in Europe by 1972. No transdermal formulations of progesterone for systemic use have been successfully marketed, in spite of efforts of pharmaceutical companies towards this goal. The low potency of transdermal progesterone has thus far precluded it as a possibility. Although no formulations of transdermal progesterone are approved for systemic use, transdermal progesterone is available in the form of creams and gels from custom compounding pharmacies in some countries, and is also available over-the-counter without a prescription in the United States. However, these preparations are unregulated and have not been adequately characterized, with low and unsubstantiated effectiveness.

Society and culture

Generic names

Progesterone is the generic name of the drug in English and its INNTooltip INN, USANTooltip United States Adopted Name, USPTooltip United States Pharmacopeia, BANTooltip British Approved Name, DCITTooltip Denominazione Comune Italiana, and JANTooltip Japanese Accepted Name, while progestérone is its name in French and its DCFTooltip Dénomination Commune Française. It is also referred to as progesteronum in Latin, progesterona in Spanish and Portuguese, and progesteron in German.

Brand names

Progesterone is marketed under a large number of brand names throughout the world. Examples of major brand names under which progesterone has been marketed include Crinone, Crinone 8%, Cyclogest, Endogest, Endometrin, Estima, Geslutin, Gesterol, Gestone, Luteina, Luteinol, Lutigest, Lutinus, Microgest, Progeffik, Progelan, Progendo, Progering, Progest, Progestaject, Progestan, Progesterone, Progestin, Progestogel, Prolutex, Proluton, Prometrium, Prontogest, Strone, Susten, Utrogest, and Utrogestan.

Availability

Progesterone is widely available in countries throughout the world in a variety of formulations. Progesterone in the form of oral capsules; vaginal capsules, tablets/inserts, and gels; and intramuscular oil have widespread availability. The following formulations/routes of progesterone have selective or more limited availability:

• A tablet of micronized progesterone which is marketed under the brand name Luteina is indicated for sublingual administration in addition to vaginal administration and is available in Poland and Ukraine.
• A progesterone suppository which is marketed under the brand name Cyclogest is indicated for rectal administration in addition to vaginal administration and is available in Cyprus, Hong Kong, India, Malaysia, Malta, Oman, Singapore, South Africa, Thailand, Tunisia, Turkey, the United Kingdom, and Vietnam.
• An aqueous solution of progesterone complexed with β-cyclodextrin for subcutaneous injection is marketed under the brand name Prolutex in the Czech Republic, Hungary, Italy, Poland, Portugal, Slovakia, Spain, and Switzerland.
• A non-systemic topical gel formulation of progesterone for local application to the breasts to treat breast pain is marketed under the brand name Progestogel and is available in Belgium, Bulgaria, Colombia, Ecuador, France, Georgia, Germany, Hong Kong, Lebanon, Peru, Romania, Russia, Serbia, Switzerland, Tunisia, Venezuela, and Vietnam. It was also formerly available in Italy, Portugal, and Spain, but was discontinued in these countries.
• A progesterone intrauterine device was previously marketed under the brand name Progestasert and was available in Canada, France, the United States, and possibly other countries, but was discontinued.
• Progesterone vaginal rings are marketed under the brand names Fertiring and Progering and are available in Chile, Ecuador, and Peru.
• A sustained-release tablet formulation of oral micronized progesterone (also known as "oral natural micronized progesterone sustained release" or "oral NMP SR") is marketed in India under the brand names Lutefix Pro (CROSMAT Technology), Dubagest SR, Gestofit SR, and Susten SR, among many others.

In addition to single-drug formulations, the following progesterone combination formulations are or have been marketed, albeit with limited availability:

• A combination pack of progesterone capsules for oral use and estradiol gel for transdermal use is marketed under the brand name Estrogel Propak in Canada.
• A combination pack of progesterone capsules and estradiol tablets for oral use is marketed in an under the brand name Duogestan in Belgium.
• Progesterone and estradiol in an aqueous suspension for use by intramuscular injection is marketed under the brand name Cristerona FP in Argentina.
• Progesterone and estradiol in microspheres in an oil solution for use by intramuscular injection is marketed under the brand name Juvenum in Mexico.
• Progesterone and estradiol benzoate in an oil solution for use by intramuscular injection is marketed under the brand names Duogynon, Duoton Fort T P, Emmenovis, Gestrygen, Lutofolone, Menovis, Mestrolar, Metrigen Fuerte, Nomestrol, Phenokinon-F, Prodiol, Pro-Estramon-S, Proger F, Progestediol, and Vermagest and is available in Belize, Egypt, El Salvador, Ethiopia, Guatemala, Honduras, Italy, Lebanon, Malaysia, Mexico, Nicaragua, Taiwan, Thailand, and Turkey.
• Progesterone and estradiol hemisuccinate in an oil solution for use by intramuscular injection is marketed under the brand name Hosterona in Argentina.
• Progesterone and estrone for use by intramuscular injection is marketed under the brand name Synergon in Monaco.

United States

As of November 2016, progesterone is available in the United States in the following formulations:

• Oral: Capsules: Prometrium (100 mg, 200 mg, 300 mg)
• Vaginal: Tablets: Endometrin (100 mg); Gels: Crinone (4%, 8%)
• Intramuscular injection: Oil: Progesterone (50 mg/mL)

A 25 mg/mL concentration of progesterone oil for intramuscular injection and a 38 mg/device progesterone intrauterine device (Progestasert) have been discontinued.

An oral combination formulation of micronized progesterone and estradiol in oil-filled capsules (brand name Bijuva) is marketed in the United States for the treatment of menopausal symptoms and endometrial hyperplasia.

Progesterone is also available in unregulated custom preparations from compounding pharmacies in the United States. In addition, transdermal progesterone is available over-the-counter in the United States, although the clinical efficacy of transdermal progesterone is controversial.

Research

Progesterone was studied as a progestogen-only injectable contraceptive, but was never marketed. Combinations of estradiol and progesterone as a macrocrystalline aqueous suspension and as an aqueous suspension of microspheres have been studied as once-a-month combined injectable contraceptives, but were likewise never marketed.

Progesterone has been assessed for the suppression of sex drive and spermatogenesis in men. In one study, 100 mg rectal suppositories of progesterone given five times per day for 9 days resulted in progesterone levels of 5.5 to 29 ng/mL and suppressed circulating testosterone and growth hormone levels by about 50% in men, but did not affect libido or erectile potency in this short treatment period. In other studies, 50 mg/day progesterone by intramuscular injection for 10 weeks in men produced azoospermia, decreased testicular size, markedly suppressed libido and erectile potency, and resulted in minimal semen volume upon ejaculation.

An oil and water nanoemulsion of progesterone (particles of <1 mm in diameter) using micellar nanoparticle technology for transdermal administration known as Progestsorb NE was under development by Novavax for use in menopausal hormone therapy in the 2000s. However, development was discontinued in 2007 and the formulation was never marketed.

References

1. Adler N, Pfaff D, Goy RW (6 December 2012). Handbook of Behavioral Neurobiology Volume 7 Reproduction (1st ed.). New York: Plenum Press. p. 189. ISBN 978-1-4684-4834-4. Retrieved 4 July 2015.
2. "Regulatory Decision Summary for pms-Progesterone". Drug and Health Product Register. 23 October 2014.
3. "Reproductive health". Health Canada. 9 May 2018. Retrieved 13 April 2024.
4. "Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Retrieved 25 March 2024.
5. ^ Levine H, Watson N (March 2000). "Comparison of the pharmacokinetics of crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women(3)". Fertility and Sterility. 73 (3): 516–521. doi:10.1016/S0015-0282(99)00553-1. PMID 10689005.
6. Griesinger G, Tournaye H, Macklon N, Petraglia F, Arck P, Blockeel C, et al. (February 2019). "Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction". Reproductive Biomedicine Online. 38 (2): 249–259. doi:10.1016/j.rbmo.2018.11.017. PMID 30595525.
7. Pandya MR, Gopeenathan P, Gopinath PM, Das SK, Sauhta M, Shinde V (2016). "Evaluating the clinical efficacy and safety of progestogens in the management of threatened and recurrent miscarriage in early pregnancy-A review of the literature". Indian Journal of Obstetrics and Gynecology Research. 3 (2): 157. doi:10.5958/2394-2754.2016.00043.6. ISSN 2394-2746. S2CID 36586762.
8. Paulson RJ, Collins MG, Yankov VI (November 2014). "Progesterone pharmacokinetics and pharmacodynamics with 3 dosages and 2 regimens of an effervescent micronized progesterone vaginal insert". The Journal of Clinical Endocrinology and Metabolism. 99 (11): 4241–4249. doi:10.1210/jc.2013-3937. PMID 24606090.
9. Fritz MA, Speroff L (28 March 2012). Clinical Gynecologic Endocrinology and Infertility. Lippincott Williams & Wilkins. pp. 44–. ISBN 978-1-4511-4847-3.
10. Marshall WJ, Bangert SK (2008). Clinical Chemistry. Elsevier Health Sciences. pp. 192–. ISBN 978-0-7234-3455-9.
11. ^ Pickar JH, Bon C, Amadio JM, Mirkin S, Bernick B (December 2015). "Pharmacokinetics of the first combination 17β-estradiol/progesterone capsule in clinical development for menopausal hormone therapy". Menopause. 22 (12): 1308–1316. doi:10.1097/GME.0000000000000467. PMC 4666011. PMID 25944519.
12. ^ Khomyak NV, Mamchur VI, Khomyak EV (2014). "Клинико-фармакологические особенности современных лекарственных форм микронизированного прогестерона, применяющихся во время беременности" [Clinical and pharmacological features of modern dosage forms of micronized progesterone used during pregnancy.] (PDF). Доровье [Health]. 4: 90.
13. ^ "Crinone® 4% and Crinone® 8% (progesterone gel)" (PDF). Watson Pharma, Inc. U.S. Food and Drug Administration. August 2013.
14. Mircioiu C, Perju A, Griu E, Calin G, Neagu A, Enachescu D, et al. (1998). "Pharmacokinetics of progesterone in postmenopausal women: 2. Pharmacokinetics following percutaneous administration". European Journal of Drug Metabolism and Pharmacokinetics. 23 (3): 397–402. doi:10.1007/BF03192300. PMID 9842983. S2CID 32772029.
15. Simon JA, Robinson DE, Andrews MC, Hildebrand JR, Rocci ML, Blake RE, et al. (July 1993). "The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone". Fertility and Sterility. 60 (1): 26–33. doi:10.1016/S0015-0282(16)56031-2. PMID 8513955.
16. ^ Cometti B (November 2015). "Pharmaceutical and clinical development of a novel progesterone formulation". Acta Obstetricia et Gynecologica Scandinavica. 94 (Suppl 161): 28–37. doi:10.1111/aogs.12765. PMID 26342177. S2CID 31974637. The administration of progesterone in injectable or vaginal form is more efficient than by the oral route, since it avoids the metabolic losses of progesterone encountered with oral administration resulting from the hepatic first-pass effect (32). In addition, the injectable forms avoid the need for higher doses that cause a fairly large number of side-effects, such as somnolence, sedation, anxiety, irritability and depression (33).
17. ^ Aufrère MB, Benson H (June 1976). "Progesterone: an overview and recent advances". Journal of Pharmaceutical Sciences. 65 (6): 783–800. doi:10.1002/jps.2600650602. PMID 945344.
18. "Prometrium (progesterone, USP) Capsules 100 mg" (PDF). Solvay Pharmaceuticals, Inc. U.S. Food and Drug Administration. 1998.
19. "Progesterone Injection USP in Sesame Oil for Intramuscular Use Only Rx Only" (PDF). U.S. Food and Drug Administration. January 2007.
20. ^ Kuhl H (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
21. ^ Wesp LM, Deutsch MB (March 2017). "Hormonal and Surgical Treatment Options for Transgender Women and Transfeminine Spectrum Persons". The Psychiatric Clinics of North America. 40 (1): 99–111. doi:10.1016/j.psc.2016.10.006. PMID 28159148.
22. ^ Ruan X, Mueck AO (November 2014). "Systemic progesterone therapy--oral, vaginal, injections and even transdermal?". Maturitas. 79 (3): 248–255. doi:10.1016/j.maturitas.2014.07.009. PMID 25113944.
23. Filicori M (November 2015). "Clinical roles and applications of progesterone in reproductive medicine: an overview". Acta Obstetricia et Gynecologica Scandinavica. 94 (Suppl 161): 3–7. doi:10.1111/aogs.12791. PMID 26443945.
24. ^ Ciampaglia W, Cognigni GE (November 2015). "Clinical use of progesterone in infertility and assisted reproduction". Acta Obstetricia et Gynecologica Scandinavica. 94 (Suppl 161): 17–27. doi:10.1111/aogs.12770. PMID 26345161. S2CID 40753277.
25. Choi SJ (September 2017). "Use of progesterone supplement therapy for prevention of preterm birth: review of literatures". Obstetrics & Gynecology Science. 60 (5): 405–420. doi:10.5468/ogs.2017.60.5.405. PMC 5621069. PMID 28989916.
26. ^ Whitaker A, Gilliam M (2014). Contraception for Adolescent and Young Adult Women. Springer. p. 98. ISBN 978-1-4614-6579-9.
27. ^ Chaudhuri (2007). Practice of Fertility Control: A Comprehensive Manual (7Th ed.). Elsevier India. pp. 153–. ISBN 978-81-312-1150-2.
28. ^ Goletiani NV, Keith DR, Gorsky SJ (October 2007). "Progesterone: review of safety for clinical studies". Experimental and Clinical Psychopharmacology. 15 (5): 427–444. doi:10.1037/1064-1297.15.5.427. PMID 17924777.
29. ^ Stute P, Neulen J, Wildt L (August 2016). "The impact of micronized progesterone on the endometrium: a systematic review" (PDF). Climacteric. 19 (4): 316–328. doi:10.1080/13697137.2016.1187123. PMID 27277331.
30. ^ Josimovich JB (11 November 2013). Gynecologic Endocrinology. Springer Science & Business Media. pp. 9, 25–29, 139. ISBN 978-1-4613-2157-6.
31. ^ Coutinho EM, Segal SJ (1999). Is Menstruation Obsolete?. Oxford University Press. pp. 31–. ISBN 978-0-19-513021-8.
32. ^ Seaman B (4 January 2011). The Greatest Experiment Ever Performed on Women: Exploding the Estrogen Myth. Seven Stories Press. pp. 27–. ISBN 978-1-60980-062-8.
33. ^ Simon JA (December 1995). "Micronized progesterone: vaginal and oral uses". Clinical Obstetrics and Gynecology. 38 (4): 902–914. doi:10.1097/00003081-199538040-00024. PMID 8616985.
34. ^ Csech J, Gervais C (September 1982). "" [Utrogestan]. Soins. Gynécologie, Obstétrique, Puériculture, Pédiatrie (in French) (16): 45–46. PMID 6925387.
35. "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
36. "Progesterone Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
37. ^ Archer DF, Bernick BA, Mirkin S (August 2019). "A combined, bioidentical, oral, 17β-estradiol and progesterone capsule for the treatment of moderate to severe vasomotor symptoms due to menopause". Expert Review of Clinical Pharmacology. 12 (8): 729–739. doi:10.1080/17512433.2019.1637731. PMID 31282768.
38. ^ Eden J (February 2017). "The endometrial and breast safety of menopausal hormone therapy containing micronised progesterone: A short review". The Australian & New Zealand Journal of Obstetrics & Gynaecology. 57 (1): 12–15. doi:10.1111/ajo.12583. PMID 28251642. S2CID 206990125.
39. ^ Mirkin S (August 2018). "Evidence on the use of progesterone in menopausal hormone therapy". Climacteric. 21 (4): 346–354. doi:10.1080/13697137.2018.1455657. PMID 29630427.
40. Mueck AO, Ruan X (December 2019). "Will estradiol/progesterone capsules for oral use become the best choice for menopausal hormone therapy?". Climacteric. 22 (6): 535–537. doi:10.1080/13697137.2019.1663625. PMID 31612748.
41. Lobo RA, Liu J, Stanczyk FZ, Constantine GD, Pickar JH, Shadiack AM, et al. (July 2019). "Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules)". Menopause. 26 (7): 720–727. doi:10.1097/GME.0000000000001306. PMC 6636803. PMID 30694918.
42. ^ Gompel A (August 2018). "Progesterone, progestins and the endometrium in perimenopause and in menopausal hormone therapy". Climacteric. 21 (4): 321–325. doi:10.1080/13697137.2018.1446932. PMID 29583028. S2CID 4422872.
43. Warren MP (August 2018). "Vaginal progesterone and the vaginal first-pass effect". Climacteric. 21 (4): 355–357. doi:10.1080/13697137.2018.1450856. PMID 29583019. S2CID 4419927.
44. Gompel A (April 2012). "Micronized progesterone and its impact on the endometrium and breast vs. progestogens". Climacteric. 15 (Suppl 1): 18–25. doi:10.3109/13697137.2012.669584. PMID 22432812. S2CID 17700754.
45. ^ Stanczyk FZ (December 2014). "Treatment of postmenopausal women with topical progesterone creams and gels: are they effective?". Climacteric. 17 (Suppl 2): 8–11. doi:10.3109/13697137.2014.944496. PMID 25196424. S2CID 20019151.
46. ^ Stanczyk FZ, Paulson RJ, Roy S (March 2005). "Percutaneous administration of progesterone: blood levels and endometrial protection". Menopause. 12 (2): 232–237. doi:10.1097/00042192-200512020-00019. PMID 15772572. S2CID 10982395.
47. ^ Prior JC (August 2018). "Progesterone for treatment of symptomatic menopausal women". Climacteric. 21 (4): 358–365. doi:10.1080/13697137.2018.1472567. PMID 29962247.
48. Schumacher M, Guennoun R, Ghoumari A, Massaad C, Robert F, El-Etr M, et al. (June 2007). "Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system". Endocrine Reviews. 28 (4): 387–439. doi:10.1210/er.2006-0050. PMID 17431228.
49. Brinton RD, Thompson RF, Foy MR, Baudry M, Wang J, Finch CE, et al. (May 2008). "Progesterone receptors: form and function in brain". Frontiers in Neuroendocrinology. 29 (2): 313–339. doi:10.1016/j.yfrne.2008.02.001. PMC 2398769. PMID 18374402.
50. Worsley R, Santoro N, Miller KK, Parish SJ, Davis SR (March 2016). "Hormones and Female Sexual Dysfunction: Beyond Estrogens and Androgens--Findings from the Fourth International Consultation on Sexual Medicine". The Journal of Sexual Medicine. 13 (3): 283–290. doi:10.1016/j.jsxm.2015.12.014. PMID 26944460.
51. Prior JC (August 2018). "Progesterone for the prevention and treatment of osteoporosis in women". Climacteric. 21 (4): 366–374. doi:10.1080/13697137.2018.1467400. PMID 29962257.
52. Raine-Fenning NJ, Brincat MP, Muscat-Baron Y (2003). "Skin aging and menopause : implications for treatment". American Journal of Clinical Dermatology. 4 (6): 371–378. doi:10.2165/00128071-200304060-00001. PMID 12762829. S2CID 20392538.
53. Holzer G, Riegler E, Hönigsmann H, Farokhnia S, Schmidt JB (September 2005). "Effects and side-effects of 2% progesterone cream on the skin of peri- and postmenopausal women: results from a double-blind, vehicle-controlled, randomized study". The British Journal of Dermatology. 153 (3): 626–634. doi:10.1111/j.1365-2133.2005.06685.x. PMID 16120154. S2CID 6077829.
54. Mirkin S, Amadio JM, Bernick BA, Pickar JH, Archer DF (May 2015). "17β-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence review". Maturitas. 81 (1): 28–35. doi:10.1016/j.maturitas.2015.02.266. PMID 25835751.
55. ^ World Professional Association for Transgender Health (September 2011), Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People, Seventh Version (PDF), archived from the original (PDF) on 6 January 2016
56. ^ Ettner R, Monstrey S, Coleman E (20 May 2016). Principles of Transgender Medicine and Surgery. Routledge. pp. 170–. ISBN 978-1-317-51460-2.
57. ^ Wierckx K, Gooren L, T'Sjoen G (May 2014). "Clinical review: Breast development in trans women receiving cross-sex hormones". The Journal of Sexual Medicine. 11 (5): 1240–1247. doi:10.1111/jsm.12487. PMID 24618412.
58. White CP, Hitchcock CL, Vigna YM, Prior JC (2011). "Fluid Retention over the Menstrual Cycle: 1-Year Data from the Prospective Ovulation Cohort". Obstetrics and Gynecology International. 2011: 138451. doi:10.1155/2011/138451. PMC 3154522. PMID 21845193.
59. Copstead-Kirkhorn EC, Banasik JL (25 June 2014). Pathophysiology - E-Book. Elsevier Health Sciences. pp. 660–. ISBN 978-0-323-29317-4. Throughout the reproductive years, some women note swelling of the breast around the latter part of each menstrual cycle before the onset of menstruation. The water retention and subsequent swelling of breast tissue during this phase of the menstrual cycle are thought to be due to high levels of circulating progesterone stimulating the secretory cells of the breast.
60. Farage MA, Neill S, MacLean AB (January 2009). "Physiological changes associated with the menstrual cycle: a review". Obstetrical & Gynecological Survey. 64 (1): 58–72. doi:10.1097/OGX.0b013e3181932a37. PMID 19099613. S2CID 22293838.
61. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M (February 2003). "Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study". American Journal of Obstetrics and Gynecology. 188 (2): 419–424. doi:10.1067/mob.2003.41. PMID 12592250. S2CID 14904733.
62. Harris G (2 May 2011). "Hormone Is Said to Cut Risk of Premature Birth". The New York Times. Retrieved 5 May 2011.
63. O'Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S, et al. (October 2007). "Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial". Ultrasound in Obstetrics & Gynecology. 30 (5): 687–696. doi:10.1002/uog.5158. PMID 17899572. S2CID 31181784.
64. DeFranco EA, O'Brien JM, Adair CD, Lewis DF, Hall DR, Fusey S, et al. (October 2007). "Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial". Ultrasound in Obstetrics & Gynecology. 30 (5): 697–705. doi:10.1002/uog.5159. PMID 17899571. S2CID 15577369.
65. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH (August 2007). "Progesterone and the risk of preterm birth among women with a short cervix". The New England Journal of Medicine. 357 (5): 462–469. doi:10.1056/NEJMoa067815. PMID 17671254. S2CID 14884358.
66. Romero R (October 2007). "Prevention of spontaneous preterm birth: the role of sonographic cervical length in identifying patients who may benefit from progesterone treatment". Ultrasound in Obstetrics & Gynecology. 30 (5): 675–686. doi:10.1002/uog.5174. PMID 17899585. S2CID 46366053.
67. Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK, Khandelwal M, et al. (July 2011). "Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial". Ultrasound in Obstetrics & Gynecology. 38 (1): 18–31. doi:10.1002/uog.9017. PMC 3482512. PMID 21472815.
68. Doheny K (14 December 2011). "Hormone Treatment May Drastically Reduce Preterm Births". WebMD.
69. "Progesterone helps cut risk of pre-term birth". Women's health. msnbc.com. 14 December 2011. Archived from the original on 15 December 2011. Retrieved 14 December 2011.
70. Yanushpolsky EH (March 2015). "Luteal phase support in in vitro fertilization". Seminars in Reproductive Medicine. 33 (2): 118–127. doi:10.1055/s-0035-1545363. PMID 25734349.
71. Palomba S, Santagni S, La Sala GB (November 2015). "Progesterone administration for luteal phase deficiency in human reproduction: an old or new issue?". Journal of Ovarian Research. 8: 77. doi:10.1186/s13048-015-0205-8. PMC 4653859. PMID 26585269.
72. Czyzyk A, Podfigurna A, Genazzani AR, Meczekalski B (June 2017). "The role of progesterone therapy in early pregnancy: from physiological role to therapeutic utility". Gynecological Endocrinology. 33 (6): 421–424. doi:10.1080/09513590.2017.1291615. PMID 28277122. S2CID 3610323.
73. ^ Falcone T, Hurd WW (2007). Clinical Reproductive Medicine and Surgery. Elsevier Health Sciences. pp. 406–. ISBN 978-0-323-03309-1.
74. Sweet MG, Schmidt-Dalton TA, Weiss PM, Madsen KP (January 2012). "Evaluation and management of abnormal uterine bleeding in premenopausal women" (PDF). American Family Physician. 85 (1): 35–43. PMID 22230306.
75. Hickey M, Higham JM, Fraser I (September 2012). "Progestogens with or without oestrogen for irregular uterine bleeding associated with anovulation". The Cochrane Database of Systematic Reviews. 2012 (9): CD001895. doi:10.1002/14651858.CD001895.pub3. PMC 7061495. PMID 22972055.
76. Wathen PI, Henderson MC, Witz CA (March 1995). "Abnormal uterine bleeding". The Medical Clinics of North America. 79 (2): 329–344. doi:10.1016/S0025-7125(16)30071-2. PMID 7877394.
77. Grossman D, White K, Harris L, Reeves M, Blumenthal PD, Winikoff B, et al. (September 2015). "Continuing pregnancy after mifepristone and "reversal" of first-trimester medical abortion: a systematic review". Contraception. 92 (3): 206–211. doi:10.1016/j.contraception.2015.06.001. PMID 26057457.
78. Ma J, Huang S, Qin S, You C, Zeng Y (December 2016). "Progesterone for acute traumatic brain injury". The Cochrane Database of Systematic Reviews. 12 (12): CD008409. doi:10.1002/14651858.CD008409.pub4. PMC 6463867. PMID 28005271.
79. Unger WP (1 February 1995). "Androgenetic alopecia and its treatment. A historical overview". Hair Transplantation (Third ed.). Taylor & Francis. pp. 1–33. ISBN 978-0-8247-9363-0.
80. ^ Sawaya ME, Shapiro J (January 2000). "Androgenetic alopecia. New approved and unapproved treatments". Dermatologic Clinics. 18 (1): 47–61, viii. doi:10.1016/S0733-8635(05)70146-7. PMID 10626111.
81. ^ Price VH (1988). "Androgenetic alopecia and hair growth promotion state of the art: present and future". Clinics in Dermatology. 6 (4): 218–227. doi:10.1016/0738-081X(88)90090-9. PMID 3063373.
82. Martínez FM (2012). "Hair loss in women". Handbook of hair in health and disease. Human Health Handbooks no. 1. Vol. 1. pp. 70–97. doi:10.3920/978-90-8686-728-8_4 (inactive 1 November 2024). ISBN 978-90-8686-728-8. ISSN 2212-375X.{{cite book}}: CS1 maint: DOI inactive as of November 2024 (link)
83. ^ Sawaya ME, Hordinsky MK (January 1993). "The antiandrogens. When and how they should be used". Dermatologic Clinics. 11 (1): 65–72. doi:10.1016/S0733-8635(18)30283-3. PMID 8435919.
84. Lourith N, Kanlayavattanakul M (September 2013). "Hair loss and herbs for treatment". Journal of Cosmetic Dermatology. 12 (3): 210–222. doi:10.1111/jocd.12051. PMID 23992163. S2CID 5094700.
85. ^ van Keep PA, Utian WH (6 December 2012). The Premenstrual Syndrome: Proceedings of a workshop held during the Sixth International Congress of Psychosomatic Obstetrics and Gynecology, Berlin, September 1980. Springer Science & Business Media. pp. 51–53. ISBN 978-94-011-6255-5.
86. Bińkowska M, Woroń J (June 2015). "Progestogens in menopausal hormone therapy". Przeglad Menopauzalny = Menopause Review. 14 (2): 134–143. doi:10.5114/pm.2015.52154. PMC 4498031. PMID 26327902.
87. ^ Shaw RW, Luesley D, Monga AK (1 October 2010). Gynaecology E-Book: Expert Consult: Online and Print. Elsevier Health Sciences. pp. 417–. ISBN 978-0-7020-4838-8.
88. ^ Smith RL, Pruthi S, Fitzpatrick LA (March 2004). "Evaluation and management of breast pain". Mayo Clinic Proceedings. 79 (3): 353–372. doi:10.4065/79.3.353. PMID 15008609.
89. ^ Dickerson LM, Mazyck PJ, Hunter MH (April 2003). "Premenstrual syndrome". American Family Physician. 67 (8): 1743–1752. PMID 12725453.
90. Ford O, Lethaby A, Roberts H, Mol BW (March 2012). "Progesterone for premenstrual syndrome". The Cochrane Database of Systematic Reviews. 2012 (3): CD003415. doi:10.1002/14651858.CD003415.pub4. PMC 7154383. PMID 22419287.
91. Wyatt K, Dimmock P, Jones P, Obhrai M, O'Brien S (October 2001). "Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review". BMJ. 323 (7316): 776–780. doi:10.1136/bmj.323.7316.776. PMC 57352. PMID 11588078.
92. Devinsky O, Schachter S, Pacia S (1 January 2005). Complementary and Alternative Therapies for Epilepsy. Demos Medical Publishing. pp. 378–. ISBN 978-1-934559-08-6.
93. ^ "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Retrieved 29 November 2016.
94. ^ "Progesterone".
95. ^ "Micromedex Products: Please Login".
96. ^ Kaunitz AM, Kaunitz JD (September 2015). "Compounded bioidentical hormone therapy: time for a reality check?". Menopause. 22 (9): 919–920. doi:10.1097/GME.0000000000000484. PMID 26035149.
97. ^ Pinkerton JV, Pickar JH (February 2016). "Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy". Menopause. 23 (2): 215–223. doi:10.1097/GME.0000000000000523. PMC 4927324. PMID 26418479.
98. ^ Hermann AC, Nafziger AN, Victory J, Kulawy R, Rocci ML, Bertino JS (June 2005). "Over-the-counter progesterone cream produces significant drug exposure compared to a food and drug administration-approved oral progesterone product". Journal of Clinical Pharmacology. 45 (6): 614–619. doi:10.1177/0091270005276621. PMID 15901742. S2CID 28399314.
99. "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Retrieved 26 July 2018.
100. Engel J, Kleemann A, Kutscher B, Reichert D (14 May 2014). Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs. Thieme. pp. 1145–. ISBN 978-3-13-179275-4.
101. Becker KL (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 2168–. ISBN 978-0-7817-1750-2.
102. ^ Anita MV, Jain S, Goel N (31 July 2018). Use of Progestogens in Clinical Practice of Obstetrics and Gynecology. JP Medical Ltd. pp. 4–. ISBN 978-93-5270-218-3.
103. ^ Sauer MV (1 March 2013). Principles of Oocyte and Embryo Donation. Springer Science & Business Media. pp. 7, 117–118. ISBN 978-1-4471-2392-7.
104. Elder K, Dale B (2 December 2010). In-Vitro Fertilization. Cambridge University Press. pp. 26–. ISBN 978-1-139-49285-0.
105. "PROSPHERE CARNOT". Archived from the original on 30 December 2019.
106. Heinrich Kahr (8 March 2013). Konservative Therapie der Frauenkrankheiten: Anzeigen, Grenzen und Methoden Einschliesslich der Rezeptur. Springer-Verlag. pp. 21–. ISBN 978-3-7091-5694-0.
107. ^ Basic Sex Hormone Therapy. Schering A.G. 1962. p. 96.
108. ^ Current Medicine and Drugs. 1962. p. 40. Primolut Intravenous (Schering A.G. Berlin)
109. ^ Haleem S, Khan MI (March 2015). "Changing Indian Market Trends of NMP: A Review" (PDF). International Journal of Pharma Research & Review. 4 (3): 28–30. ISSN 2278-6074. S2CID 74224514.
110. ^ Aschenbrenner DS, Venable SJ (2009). Drug Therapy in Nursing. Lippincott Williams & Wilkins. pp. 1150–. ISBN 978-0-7817-6587-9.
111. ^ Moini J (29 October 2008). Fundamental Pharmacology for Pharmacy Technicians. Cengage Learning. pp. 322–. ISBN 978-1-111-80040-6.
112. ^ Wang-Cheng R, Neuner JM, Barnabei VM (2007). Menopause. ACP Press. p. 97. ISBN 978-1-930513-83-9.
113. ^ Bergemann N, Ariecher-Rössler A (27 December 2005). Estrogen Effects in Psychiatric Disorders. Springer Science & Business Media. p. 179. ISBN 978-3-211-27063-9.
114. ^ Henderson VW (August 2018). "Progesterone and human cognition". Climacteric. 21 (4): 333–340. doi:10.1080/13697137.2018.1476484. PMC 6309195. PMID 29852783.
115. ^ Stein DG (June 2005). "The case for progesterone". Annals of the New York Academy of Sciences. 1052 (1): 152–169. Bibcode:2005NYASA1052..152S. doi:10.1196/annals.1347.011. PMID 16024758. S2CID 34913189.
116. ^ Freeman EW, Weinstock L, Rickels K, Sondheimer SJ, Coutifaris C (March 1992). "A placebo-controlled study of effects of oral progesterone on performance and mood". British Journal of Clinical Pharmacology. 33 (3): 293–298. doi:10.1111/j.1365-2125.1992.tb04038.x. PMC 1381278. PMID 1576050.
117. ^ North American Menopause Society (2003). "Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society". Menopause. 10 (2): 113–132. doi:10.1097/00042192-200310020-00003. PMID 12627037.
118. Söderpalm AH, Lindsey S, Purdy RH, Hauger R, de Harriet W (April 2004). "Administration of progesterone produces mild sedative-like effects in men and women". Psychoneuroendocrinology. 29 (3): 339–354. doi:10.1016/s0306-4530(03)00033-7. PMID 14644065. S2CID 21796848.
119. ^ Tausk M (30 January 1971). "Various Other Effects of Progesterone". In Bengtsson LP, Tausk M (eds.). Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Agents. Pergamon Press. pp. 375–387. ISBN 978-0-08-015745-0.
120. ^ Kopell BS (1969). "The Role of Progestins and Progesterone in Brain Function and Behavior". Metabolic Effects of Gonadal Hormones and Contraceptive Steroids. Springer. pp. 649–667. doi:10.1007/978-1-4684-1782-1_48. ISBN 978-1-4684-1784-5.
121. ^ Merryman W, Boiman R, Barnes L, Rothchild I (December 1954). "Progesterone anesthesia in human subjects". The Journal of Clinical Endocrinology and Metabolism. 14 (12): 1567–1569. doi:10.1210/jcem-14-12-1567. PMID 13211793.
122. Arafat ES, Hargrove JT, Maxson WS, Desiderio DM, Wentz AC, Andersen RN (November 1988). "Sedative and hypnotic effects of oral administration of micronized progesterone may be mediated through its metabolites". American Journal of Obstetrics and Gynecology. 159 (5): 1203–1209. doi:10.1016/0002-9378(88)90448-6. PMID 3189454.
123. ^ de Ziegler D, Fanchin R (2000). "Progesterone and progestins: applications in gynecology". Steroids. 65 (10–11): 671–679. doi:10.1016/s0039-128x(00)00123-9. PMID 11108875. S2CID 5867301.
124. Spicer DV, Ursin G, Pike MC (May 1996). "Progesterone concentrations--physiologic or pharmacologic?". Fertility and Sterility. 65 (5): 1077–1078. doi:10.1016/s0015-0282(16)58295-8. PMID 8612843.
125. Martin LJ, Minkin S, Boyd NF (September 2009). "Hormone therapy, mammographic density, and breast cancer risk". Maturitas. 64 (1): 20–26. doi:10.1016/j.maturitas.2009.07.009. PMID 19709825.
126. ^ Stute P, Wildt L, Neulen J (April 2018). "The impact of micronized progesterone on breast cancer risk: a systematic review" (PDF). Climacteric. 21 (2): 111–122. doi:10.1080/13697137.2017.1421925. PMID 29384406.
127. ^ Yang Z, Hu Y, Zhang J, Xu L, Zeng R, Kang D (February 2017). "Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis". Gynecological Endocrinology. 33 (2): 87–92. doi:10.1080/09513590.2016.1248932. PMID 27898258. S2CID 205631264.
128. ^ Lambrinoudaki I (April 2014). "Progestogens in postmenopausal hormone therapy and the risk of breast cancer". Maturitas. 77 (4): 311–317. doi:10.1016/j.maturitas.2014.01.001. PMID 24485796.
129. ^ Kuhl H, Schneider HP (August 2013). "Progesterone--promoter or inhibitor of breast cancer". Climacteric. 16 (Suppl 1): 54–68. doi:10.3109/13697137.2013.768806. PMID 23336704. S2CID 20808536.
130. ^ Davey DA (October 2018). "Menopausal hormone therapy: a better and safer future". Climacteric. 21 (5): 454–461. doi:10.1080/13697137.2018.1439915. PMID 29526116. S2CID 3850275.
131. Collaborative Group on Hormonal Factors in Breast Cancer (September 2019). "Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence". Lancet. 394 (10204): 1159–1168. doi:10.1016/S0140-6736(19)31709-X. PMC 6891893. PMID 31474332.
132. ^ Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, et al. (March 2016). "Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol". The New England Journal of Medicine. 374 (13): 1221–1231. doi:10.1056/NEJMoa1505241. PMC 4921205. PMID 27028912.
133. ^ Scarabin PY (August 2018). "Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis". Climacteric. 21 (4): 341–345. doi:10.1080/13697137.2018.1446931. PMID 29570359. S2CID 4229701.
134. Stanczyk FZ, Hapgood JP, Winer S, Mishell DR (April 2013). "Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects". Endocrine Reviews. 34 (2): 171–208. doi:10.1210/er.2012-1008. PMC 3610676. PMID 23238854.
135. Plant TM, Zeleznik AJ (15 November 2014). Knobil and Neill's Physiology of Reproduction. Academic Press. pp. 2289, 2386. ISBN 978-0-12-397769-4.
136. Schweizer E, Case WG, Garcia-Espana F, Greenblatt DJ, Rickels K (February 1995). "Progesterone co-administration in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and taper outcome". Psychopharmacology. 117 (4): 424–429. doi:10.1007/bf02246214. PMID 7604143. S2CID 8221132.
137. Keefe DL, Sarrel P (April 1996). "Dependency on progesterone in woman with self-diagnosed premenstrual syndrome". Lancet. 347 (9009): 1182. doi:10.1016/s0140-6736(96)90639-x. PMID 8609776. S2CID 5446017.
138. Pinna G, Agis-Balboa RC, Pibiri F, Nelson M, Guidotti A, Costa E (October 2008). "Neurosteroid biosynthesis regulates sexually dimorphic fear and aggressive behavior in mice". Neurochemical Research. 33 (10): 1990–2007. doi:10.1007/s11064-008-9718-5. PMID 18473173. S2CID 19338424.
139. Babalonis S, Lile JA, Martin CA, Kelly TH (June 2011). "Physiological doses of progesterone potentiate the effects of triazolam in healthy, premenopausal women". Psychopharmacology. 215 (3): 429–439. doi:10.1007/s00213-011-2206-7. PMC 3137367. PMID 21350928.
140. "Progesterone abuse". Reactions Weekly. 599 (1): 9. 1996. doi:10.2165/00128415-199605990-00031. ISSN 1179-2051. S2CID 195107326.
141. Traish AM, Mulgaonkar A, Giordano N (June 2014). "The dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depression". Korean Journal of Urology. 55 (6): 367–379. doi:10.4111/kju.2014.55.6.367. PMC 4064044. PMID 24955220.
142. Meyer L, Venard C, Schaeffer V, Patte-Mensah C, Mensah-Nyagan AG (April 2008). "The biological activity of 3alpha-hydroxysteroid oxido-reductase in the spinal cord regulates thermal and mechanical pain thresholds after sciatic nerve injury". Neurobiology of Disease. 30 (1): 30–41. doi:10.1016/j.nbd.2007.12.001. PMID 18291663. S2CID 5830825.
143. Pazol K, Wilson ME, Wallen K (June 2004). "Medroxyprogesterone acetate antagonizes the effects of estrogen treatment on social and sexual behavior in female macaques". The Journal of Clinical Endocrinology and Metabolism. 89 (6): 2998–3006. doi:10.1210/jc.2003-032086. PMC 1440328. PMID 15181090.
144. ^ Choi SY, Koh KH, Jeong H (February 2013). "Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone". Drug Metabolism and Disposition. 41 (2): 263–269. doi:10.1124/dmd.112.046276. PMC 3558868. PMID 22837389.
145. ^ Meanwell NA (8 December 2014). Tactics in Contemporary Drug Design. Springer. pp. 161–. ISBN 978-3-642-55041-6.
146. ^ Legato MJ, Bilezikian JP (2004). Principles of Gender-specific Medicine. Gulf Professional Publishing. pp. 146–. ISBN 978-0-12-440906-4.
147. ^ Lemke TL, Williams DA (24 January 2012). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 164–. ISBN 978-1-60913-345-0.
148. Soltysik K, Czekaj P (April 2013). "Membrane estrogen receptors - is it an alternative way of estrogen action?". Journal of Physiology and Pharmacology. 64 (2): 129–142. PMID 23756388.
149. Prossnitz ER, Barton M (May 2014). "Estrogen biology: new insights into GPER function and clinical opportunities". Molecular and Cellular Endocrinology. 389 (1–2): 71–83. doi:10.1016/j.mce.2014.02.002. PMC 4040308. PMID 24530924.
150. Rupprecht R, Reul JM, van Steensel B, Spengler D, Söder M, Berning B, et al. (October 1993). "Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands". European Journal of Pharmacology. 247 (2): 145–154. doi:10.1016/0922-4106(93)90072-H. PMID 8282004.
151. Elger W, Beier S, Pollow K, Garfield R, Shi SQ, Hillisch A (November 2003). "Conception and pharmacodynamic profile of drospirenone". Steroids. 68 (10–13): 891–905. doi:10.1016/j.steroids.2003.08.008. PMID 14667981. S2CID 41756726.
152. Baulieu E, Schumacher M (2000). "Progesterone as a neuroactive neurosteroid, with special reference to the effect of progesterone on myelination". Steroids. 65 (10–11): 605–612. doi:10.1016/s0039-128x(00)00173-2. PMID 11108866. S2CID 14952168.
153. Paul SM, Purdy RH (March 1992). "Neuroactive steroids". FASEB Journal. 6 (6): 2311–2322. doi:10.1096/fasebj.6.6.1347506. PMID 1347506. S2CID 221753076.
154. ^ Bentley PJ (1980). Endocrine Pharmacology: Physiological Basis and Therapeutic Applications. CUP Archive. pp. 264, 274. ISBN 978-0-521-22673-8.
155. Oelkers W (December 2000). "Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone". The European Journal of Contraception & Reproductive Health Care. 5 (Suppl 3): 17–24. doi:10.1080/14730782.2000.12288986. PMID 11246598. S2CID 35051390.
156. Bäckström T, Bixo M, Johansson M, Nyberg S, Ossewaarde L, Ragagnin G, et al. (February 2014). "Allopregnanolone and mood disorders". Progress in Neurobiology. 113: 88–94. doi:10.1016/j.pneurobio.2013.07.005. PMID 23978486. S2CID 207407084.
157. ^ Zutshi (2005). Hormones in Obstetrics and Gynaecology. Jaypee Brothers, Medical Publishers. pp. 74–75. ISBN 978-81-8061-427-9. It has been observed that micronized progesterone has no suppressive effects on high-density lipoprotein-cholesterol (HDL-C). Jensen et al have proved that oral micronized progesterone has no adverse effect on serum lipids. These preparations have the same antiestrogenic and antimineralocorticoid effect but no androgenic action. It does not affect aldosterone synthesis, blood pressure, carbohydrate metabolism or mood changes. No side effects have been reported as far as lipid profile, coagulation factors and blood pressure are concerned.
158. Lark S (1999). Making the Estrogen Decision. McGraw-Hill Professional. p. 22. ISBN 978-0-87983-696-2.
159. Progesterone - Drugs.com, retrieved 23 August 2015
160. Kuhl H (2011). "Pharmacology of Progestogens" (PDF). Journal für Reproduktionsmedizin und Endokrinologie-Journal of Reproductive Medicine and Endocrinology. 8 (1): 157–177.
161. ^ de Lignières B (January 1999). "Oral micronized progesterone". Clinical Therapeutics. 21 (1): 41–60, discussion 1–2. doi:10.1016/S0149-2918(00)88267-3. PMID 10090424.
162. ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 1024–. ISBN 978-1-4757-2085-3.
163. ^ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 880–. ISBN 978-3-88763-075-1.
164. Pincus G, Miyake T, Merrill AP, Longo P (November 1957). "The bioassay of progesterone". Endocrinology. 61 (5): 528–533. doi:10.1210/endo-61-5-528. PMID 13480263.
165. Basu K, Mitra AK (1990). "Effects of 3-hydrazone modification on the metabolism and protein binding of progesterone". International Journal of Pharmaceutics. 65 (1–2): 109–114. doi:10.1016/0378-5173(90)90015-V. ISSN 0378-5173.
166. Wali B, Sayeed I, Guthrie DB, Natchus MG, Turan N, Liotta DC, et al. (October 2016). "Evaluating the neurotherapeutic potential of a water-soluble progesterone analog after traumatic brain injury in rats". Neuropharmacology. 109: 148–158. doi:10.1016/j.neuropharm.2016.05.017. PMID 27267687. S2CID 19906601.
167. US 9802978, Guthrie DA, Lockwood MA, Natchus MG, Liotta DC, Stein DG, Sayeed I, "Progesterone phosphate analogs and uses related thereto", issued 31 October 2017, assigned to Emory University. 
168. MacNevin CJ, Atif F, Sayeed I, Stein DG, Liotta DC (October 2009). "Development and screening of water-soluble analogues of progesterone and allopregnanolone in models of brain injury". Journal of Medicinal Chemistry. 52 (19): 6012–6023. doi:10.1021/jm900712n. PMID 19791804. S2CID 23608386.
169. Guthrie DB, Stein DG, Liotta DC, Lockwood MA, Sayeed I, Atif F, et al. (May 2012). "Water-soluble progesterone analogues are effective, injectable treatments in animal models of traumatic brain injury". ACS Medicinal Chemistry Letters. 3 (5): 362–366. doi:10.1021/ml200303r. PMC 4025794. PMID 24900479.
170. "Progesterone conjugate - Levolta Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.
171. Die Gestagene. Springer-Verlag. 27 November 2013. pp. 5–. ISBN 978-3-642-99941-3.
172. Walker A (7 March 2008). The Menstrual Cycle. Routledge. pp. 49–. ISBN 978-1-134-71411-7.
173. Ginsburg B (6 December 2012). Premenstrual Syndrome: Ethical and Legal Implications in a Biomedical Perspective. Springer Science & Business Media. pp. 274–. ISBN 978-1-4684-5275-4.
174. ^ Die Gestagene. Springer-Verlag. 27 November 2013. pp. 1027–. ISBN 978-3-642-99941-3.
175. ^ Gerald M (2013). The Drug Book. New York, New York: Sterling Publishing. p. 186. ISBN 978-1-4027-8264-0.
176. Anita MV, Jain S, Goel N (31 July 2018). Use of Progestogens in Clinical Practice of Obstetrics and Gynecology. JP Medical Ltd. pp. 3–. ISBN 978-93-5270-218-3.
177. ^ Johnstone RW (November 1936). "Sex Hormone Therapy in Gynæcology". Edinburgh Medical Journal. 43 (11): 680–695. PMC 5303355. PMID 29648134.
178. ^ Kaufmann C (1934). "Therapeutics with Hormones of the Ovary". Proceedings of the Royal Society of Medicine. 27 (7): 849–863. doi:10.1177/003591573402700711. ISSN 0035-9157.
179. ^ Reifenstein EC (1944). "Endocrinology: A Synopsis of Normal and Pathologic Physiology, Diagnostic Procedures, and Therapy". Medical Clinics of North America. 28 (5): 1232–1276. doi:10.1016/S0025-7125(16)36180-6. ISSN 0025-7125.
180. Kaufman C (1933). "Die Behandlung der Amenorrhöe mit Hohen Dosen der Ovarialhormone" [Treatment of Amenorrhea with High Doses of Ovarian Hormones]. Klinische Wochenschrift. 12 (40): 1557–1562. doi:10.1007/BF01765673. ISSN 0023-2173. S2CID 25856898.
181. Bishop PM (April 1937). "Hormones in the Treatment of Menstrual Disturbances". British Medical Journal. 1 (3979): 763–765. doi:10.1136/bmj.1.3979.763. PMC 2088583. PMID 20780598.
182. Beattie J (July 1937). "The Use of Hormones in Obstetrics and Gynæcology". Postgraduate Medical Journal. 13 (141): 234–240. doi:10.1136/pgmj.13.141.234. PMC 2476623. PMID 21313067.
183. Djerassi C (2003). This Man's Pill: Reflections on the 50th Birthday of the Pill. Oxford University Press. pp. 21–. ISBN 978-0-19-860695-6.
184. Mishell DR (1941). "A clinical study of progesterone therapy by pellet implantation". American Journal of Obstetrics and Gynecology. 41 (4): 687–693. doi:10.1016/S0002-9378(41)90665-8. ISSN 0002-9378.
185. Foss GL (1943). "Implantation of Sex Hormone Tablets in Man". British Medical Bulletin. 1 (2): 21–22. doi:10.1093/oxfordjournals.bmb.a070135. ISSN 1471-8391.
186. ^ Greenblatt RB, Hair LQ (1945). "Absorption of Pellets of Progesterone". The Journal of Clinical Endocrinology & Metabolism. 5 (1): 38–39. doi:10.1210/jcem-5-1-38. ISSN 0021-972X. S2CID 71161306.
187. Greenblatt RB, Suran RR (February 1949). "Indications for hormonal pellets in the therapy of endocrine and gynecic disorders". American Journal of Obstetrics and Gynecology. 57 (2): 294–301. doi:10.1016/0002-9378(49)90429-9. PMID 18123090.
188. Bishop PM, Folley SJ (August 1951). "Absorption of hormone implants in man". Lancet. 2 (6676): 229–232. doi:10.1016/S0140-6736(51)93237-0. PMID 14862159.
189. ^ Rauscher H (1960). "Therapie mit Depotgestagenen". Moderne Entwicklungen auf dem Gestagengebiet. Symposion der Deutschen Gesellschaft für Endokrinologie. Springer. pp. 87–92. doi:10.1007/978-3-662-25301-4_11. ISBN 978-3-662-23272-9.
190. ^ Greenblatt RB, Clark SL (March 1957). "The use of newer progestational preparations in clinical practice". The Medical Clinics of North America. 41 (2): 587–603. doi:10.1016/S0025-7125(16)34457-1. PMID 13407238.
191. Bishop PM (1944). "Endocrine Therapy in Gynaecology and Obstetrics". BJOG: An International Journal of Obstetrics and Gynaecology. 51 (1): 51–63. doi:10.1111/j.1471-0528.1944.tb07317.x. ISSN 1470-0328. S2CID 71319436.
192. Croxatto HB, Díaz S (1987). "The place of progesterone in human contraception". Journal of Steroid Biochemistry. 27 (4–6): 991–994. doi:10.1016/0022-4731(87)90179-8. PMID 3320572.
193. Shaaban MM (1991). "Contraception with progestogens and progesterone during lactation". The Journal of Steroid Biochemistry and Molecular Biology. 40 (4–6): 705–710. doi:10.1016/0960-0760(91)90294-F. PMID 1835650. S2CID 25152238.
194. Croxatto HB, Díaz S, Peralta O, Juez G, Casado ME, Salvatierra AM, et al. (September 1982). "Fertility regulation in nursing women. II. Comparative performance of progesterone implants versus placebo and copper T". American Journal of Obstetrics and Gynecology. 144 (2): 201–208. doi:10.1016/0002-9378(82)90628-7. PMID 7114130.
195. Díaz S, Peralta O, Juez G, Herreros C, Casado ME, Salvatierra AM, et al. (October 1984). "Fertility regulation in nursing women. VI. Contraceptive effectiveness of a subdermal progesterone implant". Contraception. 30 (4): 311–325. doi:10.1016/S0010-7824(84)80023-2. PMID 6509984.
196. Masters WH, Grody MH, Magallon DT (November 1952). "Progesterone in aqueous crystalline suspension versus progesterone in oil; comparison by withdrawal bleeding tests in the human female". The Journal of Clinical Endocrinology and Metabolism. 12 (11): 1445–1453. doi:10.1210/jcem-12-11-1445. PMID 12999984.
197. Miescher K, Gasche P, Frey H (1944). "Depotwirkung von Kristallsuspensionen weiblicher Sexualhormone (Ovocyclin- und Lutocyclin-Kristallampullen). Experimentelle und theoretische Grundlagen". Helvetica Physiologica et Pharmacologica Acta. 2: 515–532. ISSN 0367-6242. OCLC 499306481.
198. Koref O, Engel P (March 1946). "Administration of progesterone in the form of microcrystals". Endocrinology. 38 (3): 214–215. doi:10.1210/endo-38-3-214. PMID 21025113.
199. ^ Kahr H (8 March 2013). Konservative Therapie der Frauenkrankheiten: Anzeigen, Grenzen und Methoden Einschliesslich der Rezeptur. Springer-Verlag. pp. 20–21. ISBN 978-3-7091-5694-0.
200. Edkins RP (1959). "The Modification of the Duration of Drug Action". Journal of Pharmacy and Pharmacology. 11 (S1): 54T–66T. doi:10.1111/j.2042-7158.1959.tb10412.x. ISSN 0022-3573. S2CID 78850713.
201. Gordon D, Horwitt BN, Segaloff A, Murison PJ, Schlosser JV (March 1952). "Hormonal therapy in cancer of the breast. III. Effect of progesterone on clinical course and hormonal excretion". Cancer. 5 (2): 275–277. doi:10.1002/1097-0142(195203)5:2<275::aid-cncr2820050213>3.0.co;2-h. PMID 14905411.
202. Bradbury JT, Long RC, Durham WC (1953). "Progesterone and estrogen requirements to induce and maintain decidua". Fertility and Sterility. 4 (1): 63–75. doi:10.1016/s0015-0282(16)31145-1. PMID 13021207.
203. Fraser IS (1998). Estrogens and Progestogens in Clinical Practice. Churchill Livingstone. p. 13. ISBN 978-0-443-04706-0.
204. "Progesterone: Uses, Dosage & Side Effects".
205. "Agolutin Depot Label" (PDF). www.sukl.cz. Archived from the original (PDF) on 19 May 2019. Retrieved 15 January 2022.
206. "Clinomin Forte Label" (PDF). www.indufar.com.py. Archived from the original (PDF) on 18 August 2020. Retrieved 15 January 2022.
207. Lens J, Overbeek GA, Polderman J (1949). "The effect of sex hormones in some organic solvents; emulsified in water". Acta Endocrinologica. 2 (4): 396–404. doi:10.1530/acta.0.0020396. PMID 18140399.
208. Ferin J (January 1952). "Relative duration of action of natural and synthetic estrogens administered parenterally in women with estrogen deficiency". The Journal of Clinical Endocrinology and Metabolism. 12 (1): 28–35. doi:10.1210/jcem-12-1-28. PMID 14907837.
209. Overbeek CA (1952). "Some Data on Emulsions of Steroid Hormones". Ciba Foundation Symposium - Steroid Hormone Administration (Book II of Colloquia on Endocrinology, Vol. 3). Novartis Foundation Symposia. John Wiley & Sons. pp. 254–262. doi:10.1002/9780470715154.ch2. ISBN 978-0-470-71515-4. ISSN 1935-4657.
210. Kimmig J (14 March 2013). Therapie der Haut- und Geschlechtskrankheiten. Springer-Verlag. pp. 508–. ISBN 978-3-642-94850-3.
211. Jores A, Nowakowski H (1960). Praktische Endokrinologie. G. Thieme. p. 295.
212. Von Numers C (1951). "Simultaneous treatment of secondary amenorrhoea with oestrogen and progesterone". Acta Endocrinologica. 6 (1): 67–89. doi:10.1530/acta.0.0060067. PMID 14810456.
213. "Neue Spezialitäten". Klinische Wochenschrift. 36 (17): 833. 1958. doi:10.1007/BF01481957. ISSN 0023-2173. S2CID 42166026.
214. ^ Garza-Flores J, Cravioto MC, Pérez-Palacios G (1992). "Steroid Injectable Contraception: Current Concepts and Perspectives". In L. R. Sitruk-Ware, C. Wayne Bardin (eds.). Contraception: newer pharmacological agents, devices, and delivery systems. M. Dekker. pp. 41–70. ISBN 978-0-8247-8700-4.
215. ^ Alvarez-Sanchez F, Brache V, Faundes A (December 1993). "Recent experience with and future directions of contraceptive implants and injectable contraceptives". Current Opinion in Obstetrics & Gynecology. 5 (6): 805–814. doi:10.1097/00001703-199312000-00016. PMID 8286694.
216. ^ Cullins VE (August 1992). "Injectable and implantable contraceptives". Current Opinion in Obstetrics & Gynecology. 4 (4): 536–543. doi:10.1097/00001703-199208000-00008. PMID 1387011. S2CID 39442952.
217. ^ Garza-Flores J (April 1994). "Pharmacokinetics of once-a-month injectable contraceptives". Contraception. 49 (4): 347–359. doi:10.1016/0010-7824(94)90032-9. PMID 8013219.
218. Garza-Flores J, Fatinikun T, Hernandez L, Ramos I, Cardenas M, Menjivar M (July 1991). "A pilot study on the assessment of a progesterone/estradiol sustained release as once-a-month-injectable contraceptive". Contraception. 44 (1): 45–59. doi:10.1016/0010-7824(91)90105-o. PMID 1893701.
219. Ekwall P, Sjoblom L (1950). "Aqueous solutions of steroid hormones". Acta Endocrinologica. 4 (2): 179–191. doi:10.1530/acta.0.0040179. PMID 15432051.
220. Basic Sex Hormone Therapy. Schering A.G. 1962. p. 93,96. Intravenous: The intravenous injection of sex hormones is restricted mainly to specific circumstances where a speedy elevation of hormone levels is required, for example, in treatment of threatened abortion. Crystalline Suspension: With crystalline suspensions the crystalline size governs the rate of absorption and therefore the duration of action. The lack of standardisation of crystalline size in commercial products plus the limits imposed by needle bore, introduces marked variations in effect. The results from emulsified forms are even more unreliable. Hormone Pellets for Implantation: The subcutaneous implantation of sterile tablets was the first means of achieving prolonged action. Such possible factors as encapsulation or extrusion and diminished absorption as the surface area of the pellet is reduced, may be a drawback. Implantation of testosterone (about eight 100 mg. pellets), repeated 6-monthly, is a satisfactory treatment for eunuchoidism and implantation of oestradiol (a 50 mg. pellet remains active for about a year or more) is sometimes a useful procedure. The implantation of progesterone is best discarded altogether; extrusion of pellets (even when placed beneath the deep fascia) and slowness of absorption, in relation to metabolic requirements, make it unsatisfactory and the new depot hormones should be given preference. Sex Hormone Preparations of Schering A.G. Berlin Trade Name: Primolut intravenous. Chemical Description: Progesterone in aqueous solution. Packing: Ampoules of 1 c. c. = 20 mg.
221. "Progesterone - IBSA". AdisInsight. Springer Nature Switzerland AG.
222. ^ Greenblatt RB, Mahesh VB, Shapiro ST (June 1964). "Physiologic and Clinical Aspects of Ovarian Hormones". Archives of Dermatology. 89 (6): 846–857. doi:10.1001/archderm.1964.01590300074022. PMID 14164973.
223. ^ Babcock JC (1964). "Synthetic Progestational Agents". Molecular Modification in Drug Design. Advances in Chemistry. Vol. 45. American Chemical Society. pp. 190–203. doi:10.1021/ba-1964-0045.ch016. ISBN 0-8412-0046-7. ISSN 0065-2393.
224. Tausk M (1968). "Practically Applicable Results of Twenty Years of Research in Endocrinology". In Jucker E (ed.). Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques. Vol. 12. Basel: Birkhäuser. pp. 137–164. doi:10.1007/978-3-0348-7065-8_3. ISBN 978-3-0348-7067-2. PMID 4307936. {{cite book}}: |journal= ignored (help)
225. ^ Bickers W (August 1949). "Progesterone; a comparison of intramuscular, oral and sublingual routes of administration". The Journal of Clinical Endocrinology and Metabolism. 9 (8): 736–742. doi:10.1210/jcem-9-8-736. PMID 18133494.
226. ^ Greenblatt RB, Barfield WE, Clark S, Brown N (August 1950). "Physiologic effectiveness of oral progesterone". The Journal of Clinical Endocrinology and Metabolism. 10 (8): 886–896. doi:10.1210/jcem-10-8-886. PMID 15436649.
227. Bickers W (July 1952). "Menstrual arrhythmias; oral estrogen and progesterone therapy". American Journal of Obstetrics and Gynecology. 64 (1): 148–154. doi:10.1016/s0002-9378(16)38745-2. PMID 14933526.
228. Mulligan WJ, Horne HW, Rock J (1952). "Cyclic oral therapy of menstrual disorders". Fertility and Sterility. 3 (4): 328–333. doi:10.1016/S0015-0282(16)30965-7. PMID 12980155.
229. ^ Fischer RH, McCOLGAN SP (September 1953). "Progesterone metabolism. II. Pregnanediol excretion following oral, sublingual and parenteral administration of progesterone". The Journal of Clinical Endocrinology and Metabolism. 13 (9): 1043–1053. doi:10.1210/jcem-13-9-1043. PMID 13084722.
230. ^ Frank R, Guterman HS (1954). "Comparison of progesterone preparations in secondary amenorrhea". Fertility and Sterility. 5 (4): 374–381. doi:10.1016/S0015-0282(16)31687-9. PMID 13183192.
231. ^ Kupperman HS, Lefkovics SC (1957). "Progesterone in problems of sterility; diagnostic and therapeutic use". Fertility and Sterility. 8 (2): 131–46, discussion, 146–8. doi:10.1016/S0015-0282(16)32642-5. PMID 13405054.
232. ^ Rock J, Garcia CR, Pincus G (1957). "Synthetic progestins in the normal human menstrual cycle". Recent Progress in Hormone Research. 13: 323–39, discussion 339–46. PMID 13477811. Archived from the original on 2 May 2019. Retrieved 2 May 2019.
233. Birnberg CH, Livingston S, Davis JG (January 1958). "Large-dose oral progesterone therapy in menstrual disorders". Obstetrics and Gynecology. 11 (1): 115–118. PMID 13504644.
234. Volk H, Escher GC, Huseby RA, Tyler FH, Cheda J (1960). "Hormonal therapy in carcinoma of the breast.I. Effect of oral progesterone on clinical course and metabolism of nitrogen and selected electrolytes and steroids". Cancer. 13 (4): 757–763. doi:10.1002/1097-0142(196007/08)13:4<757::AID-CNCR2820130417>3.0.CO;2-9. ISSN 0008-543X.
235. ^ Takeuchi-Demirci A (9 January 2018). Contraceptive Diplomacy: Reproductive Politics and Imperial Ambitions in the United States and Japan. Stanford University Press. pp. 188–191, 243. ISBN 978-1-5036-0441-4.
236. Abrams RE (February 1953). "Modern medicinals in review". American Journal of Pharmacy and the Sciences Supporting Public Health. 125 (2): 49–69. PMID 13030701. Cyclogesterin. A relatively new approach to progesterone therapy, Cyclogesterin establishes that this hormone can be effective by the oral route. Primarily indicated to induce menstruation in secondary amenorrhea by oral therapy, it contains 30 mg. of progesterone and 1 mg. of mixed natural estrogens per tablet. One tablet is given three times daily for five consecutive days and therapy is stopped. Menstruation follows in one to six days in the non-pregnant patient. The product is manufactured by the Upjohn Company.
237. Gutman J (1958). Modern Drug Encyclopedia and Therapeutic Index. Yorke Medical Group. p. 299.
238. Greenblatt RB, Rose FD (June 1962). "Delay of menses: test of progestational efficacy in induction of pseudopregnancy". Obstetrics and Gynecology. 19: 730–735. PMID 13901505.
239. Puebla RA, Greenblatt RB (September 1964). "Clomiphene Citrate in the Management of Anovulatory Uterine Bleeding1". The Journal of Clinical Endocrinology and Metabolism. 24 (9): 863–866. doi:10.1210/jcem-24-9-863. PMID 14216475.
240. United States. Patent Office (1955). Official Gazette of the United States Patent Office. U.S. Patent Office. pp. 2–.
241. Greenblatt RB (1944). "Sublingual Absorption of Progesterone and Anhydrohydroxyprogesterone". The Journal of Clinical Endocrinology & Metabolism. 4 (4): 156–158. doi:10.1210/jcem-4-4-156. ISSN 0021-972X.
242. Greenblatt RB (1944). "Perlingual Absorption of Progesterone and Anhydrohydroxyprogesterone1,2". The Journal of Clinical Endocrinology & Metabolism. 4 (7): 321–325. doi:10.1210/jcem-4-7-321. ISSN 0021-972X.
243. Soule SD, Yanow M (July 1953). "Recovery of pregnanediol from urine following administration of oral anhydrohydroxyprogesterone, buccal progesterone, and intramuscular progesterone". Obstetrics and Gynecology. 2 (1): 68–72. PMID 13073082.
244. "New Prescription Products". Journal of the American Pharmaceutical Association (Practical Pharmacy Ed.). 10 (4): 198–206. 1949. doi:10.1016/S0095-9561(16)31795-9. ISSN 0095-9561.
245. Remington JP, Cook EF, Martin EW (1951). Remington's Practice of Pharmacy: A Treatise on the Preparing, Standardizing, and Dispensing of Official and Extemporaneous Pharmaceutical Products, with Descriptions of Medicinal Substances, Their Properties, Uses and Doses. Also a Guide to Other Professional Services Rendered by the Pharmacist in Connection with Community Health. Intended for the Use of Pharmacists and Physicians and as a Textbook for Students. Mack Publishing Company. pp. 936–937.
246. Welsh AL (1951). Dermatological Formulary: A Guide for Medical Students and Resident Physicians in Dermatology. Educational Publishers. p. 155.
247. Hager HH, Kern W, List PH, Roth HJ (1969). Hagers Handbuch der Pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Ärzte und Medizinalbeamte: Wirkstoffgruppen II Chemikalien und Drogen (A-AL). Springer-Verlag. pp. 178–. ISBN 978-3-662-25655-8.
248. ^ Pincus G, Bialy G (1964). Drugs Used in Control of Reproduction. Advances in Pharmacology. Vol. 3. Academic Press. pp. 285–313. doi:10.1016/S1054-3589(08)61115-1. ISBN 978-0-12-032903-8. PMID 14232795. The original observation of Makepeace et al. (1937) that progesterone inhibited ovulation in the rabbit was substantiated by Pincus and Chang (1953). In women, 300 mg of progesterone per day taken orally resulted in ovulation inhibition in 80% of cases (Pincus, 1956). The high dosage and frequent incidence of breakthrough bleeding limited the practical application of the method. Subsequently, the utilization of potent 19-norsteroids, which could be given orally, opened the field to practical oral contraception.
249. ^ Chang MC (September 1978). "Development of the oral contraceptives". American Journal of Obstetrics and Gynecology. 132 (2): 217–219. doi:10.1016/0002-9378(78)90928-6. PMID 356615.
250. Makepeace AW, Weinstein GL, Friedman MH (1937). "The effect of progestin and progesterone on ovulation in the rabbit". American Journal of Physiology. Legacy Content. 119 (3): 512–516. doi:10.1152/ajplegacy.1937.119.3.512. ISSN 0002-9513.
251. Astwood EB, Fevold HL (1939). "Action of progesterone on the gonadotropic activity of the pituitary". American Journal of Physiology. Legacy Content. 127 (1): 192–198. doi:10.1152/ajplegacy.1939.127.1.192. ISSN 0002-9513.
252. Pincus G, Chang MC (1953). "The effects of progesterone and related compounds on ovulation and early development in the rabbit". Acta Physiologica Latino Americana. 3 (2–3): 177–183. PMID 13138262.
253. Slechta RF, Chang MC, Pincus G (1954). "Effects of progesterone and related compounds on mating and pregnancy in the rat". Fertility and Sterility. 5 (3): 282–293. doi:10.1016/S0015-0282(16)31628-4. PMID 13162007.
254. ^ Diczfalusy E (December 1965). "Probable mode of action of oral contraceptives". British Medical Journal. 2 (5475): 1394–1399. doi:10.1136/bmj.2.5475.1394. PMC 1847181. PMID 5848673. At the Fifth International Conference on Planned Parenthood in Tokyo, Pincus (1955) reported an ovulation inhibition by progesterone or norethynodrel1 taken orally by women. This report indicated the beginning of a new era in the history of contraception. That the cervical mucus might be one of the principal sites of action was suggested by the first studies of Pincus (1956, 1959) and of Ishikawa et al. (1957). These investigators found that no pregnancies occurred in women treated orally with large doses of progesterone, though ovulation was inhibited only in some 70% of the cases studied. The mechanism of protection in this method—and probably in that of Pincus (1956) and of Ishikawa et al. (1957)—must involve an effect on the cervical mucus and/or endometrium and Fallopian tubes.
255. Pincus G (1955). "Some Effects of Progesterone and Related Compounds upon Reproduction and Early Development in Mammals". The Fifth International Conference on Planned Parenthood: Theme, Overpopulation and Family Planning: Report of the Proceedings, 24-29 October, 1955, Tokyo, Japan. International Planned Parenthood Federation. pp. 175–184.
256. Stone A, Kupperman HS (1955). "The Effects of Progesterone on Ovulation: A Preliminary Report". The Fifth International Conference on Planned Parenthood: Theme, Overpopulation and Family Planning: Report of the Proceedings, 24-29 October, 1955, Tokyo, Japan. International Planned Parenthood Federation. p. 185. Archived from the original on 2 May 2019. Retrieved 2 May 2019. The results of testing the effects of progesterone on ovulation in 13 patients at the Margaret Sanger Research Bureau are presented. The patients had normal menstrual cycles and showed clear evidence of ovulation. Each patient was given 1000 of progesterone daily during the midperiod for 10 or 12 days during 16 cycles. Ovulation was inhibited in 6 cycles. No disturbance in menstrual rhythm was observed. 3 of 12 patients with longstanding infertility histories became pregnant within 2–4 months after the cessation of progesterone therapy.
257. Ishikawa M, Kyushiro F, Yoshio F, Takashi K, Masanao M, Michio M, et al. (1955). "Some Effects of Progesterone and Related Compounds upon Reproduction and Early Development in Mammals". The Fifth International Conference on Planned Parenthood: Theme, Overpopulation and Family Planning: Report of the Proceedings, 24-29 October, 1955, Tokyo, Japan. International Planned Parenthood Federation. pp. 186–187.
258. Pincus G (1956). "Some effects of progesterone and related compounds upon reproduction and early development in mammals". Acta Endocrinologica. Supplementum. 23 (Suppl 28): 18–36. doi:10.1530/acta.0.023S018. PMID 13394044. S2CID 33729147.
259. Ishikawa M, Fujii K, Furusawa Y, Kobayashi T, Makino T, Matsumoto S, et al. "Unknown". J. Jap. Family Plann. Ass. 2: 51–56.
260. Pincus G (1959). "Progestational Agents and the Control of Fertility". Vitamins and Hormones: Advances in Research and Applications. Vitamins & Hormones. Vol. 17. Academic Press. pp. 307–324. doi:10.1016/S0083-6729(08)60274-5. ISBN 978-0-12-709817-3. ISSN 0083-6729. Ishikawa et al. (1957) employing the same regime of progesterone administration also observed suppression of ovulation in a proportion of the cases taken to laparotomy. Although sexual intercourse was practised freely by the subjects of our experiments and those of Ishikawa el al., no pregnancies occurred. Since ovulation presumably took place in a proportion of cycles, the lack of any pregnancies may be due to chance, but Ishikawa et al. (1957) have presented data indicating that in women receiving oral progesterone the cervical mucus becomes impenetrable to sperm.
261. Perone N (1993). "The history of steroidal contraceptive development: the progestins". Perspectives in Biology and Medicine. 36 (3): 347–362. doi:10.1353/pbm.1993.0054. PMID 8506121. S2CID 46312750.
262. Dhont M (December 2010). "History of oral contraception". The European Journal of Contraception & Reproductive Health Care. 15 (Suppl 2): S12–S18. doi:10.3109/13625187.2010.513071. PMID 21091163. S2CID 22706524.
263. ^ Ramírez de Arellano AB, Seipp C (10 October 2017). Colonialism, Catholicism, and Contraception: A History of Birth Control in Puerto Rico. University of North Carolina Press. pp. 106–112. ISBN 978-1-4696-4001-3. Still, neither of the two researchers was completely satisfied with the results. Progesterone tended to cause "premature menses," or breakthrough bleeding, in approximately 20 percent of the cycles, an occurrence that disturbed the patients and worried Rock.17 in addition, Pincus was concerned about the failure to inhibit ovulation in all the cases. Only large doses of orally administered progesterone could insure the suppression of ovulation, and these doses were expensive. The mass use of this regimen as a birth control method was thus seriously imperiled.18
264. Marsh M, Ronner W (31 October 2008). The Fertility Doctor: John Rock and the Reproductive Revolution. JHU Press. pp. 333–. ISBN 978-1-4214-0208-6. 43. The first study used progesterone continuously rather than cyclically. Women began by taking 5 mg of stilbestrol and 50 mg of progesterone, increasing the dose of stilbestrol by 5 mg and of progesterone by 50 mg every two weeks. By the end of twelve weeks, women were taking 30 mg stilbestrol and 300 mg of progesterone. If they had vaginal bleeding at any time, the doses were increased. "Pseudopregnancy," typescript, 15 July 1954, GP-LC. Rock also summarizes his early studies in John Rock, Celso-Ramon Garcia, and Gregory Pincus, "Synthetic Progestins in the Normal Human Menstrual Cycle," Recent Progress in Hormone Research, vol. 13 (New York: Academic Press, 1957), 323-24.
265. Watkins ES (14 September 2001). On the Pill: A Social History of Oral Contraceptives, 1950-1970. Johns Hopkins University Press. ISBN 978-1-4214-0371-7. In the early 1950s, independent of Pincus's work in Worcester, Rock successfully induced pregnancy in previously infertile women by treating them for several months with estrogen and progesterone. Although the steroids prevented pregnancy during the course of therapy, some of the women conceived when the treatment ended; this phenomenon became known as the "Rock rebound effect."58 When Pincus learned of Rock's work, he asked the physician to join forces in the hunt for an ovulation inhibitor, and Rock agreed. Pincus suggested two changes in the experimental regimen: use only progesterone (estrogen promoted cancer in laboratory animals) and administer the hormone for twenty days each month (to allow a period of menstruation). Rock achieved the same rate of success in curing infertility (about 15%), but a significant problem remained: tests indicated that about 15 percent of the women ovulated while taking the progesterone.59 Pincus and Rock needed to find an orally active compound that would completely inhibit ovulation. It was time to test the 19-nor steroids in humans.
266. Pincus G, Chang MC, Hafez ES, Zarrow MX, Merrill A (November 1956). "Effects of certain 19-nor steroids on reproductive processes in animals". Science. 124 (3227): 890–891. Bibcode:1956Sci...124..890P. doi:10.1126/science.124.3227.890-a. PMID 13380400. S2CID 31577493.
267. Garcia CR, Pincus G, Rock J (November 1956). "Effects of certain 19-nor steroids on the normal human menstrual cycle". Science. 124 (3227): 891–893. Bibcode:1956Sci...124..891R. doi:10.1126/science.124.3227.891. PMID 13380401.
268. Marks L (2010). Sexual Chemistry: A History of the Contraceptive Pill. Yale University Press. pp. 75–. ISBN 978-0-300-16791-7.
269. Christin-Maitre S (February 2013). "History of oral contraceptive drugs and their use worldwide". Best Practice & Research. Clinical Endocrinology & Metabolism. 27 (1): 3–12. doi:10.1016/j.beem.2012.11.004. PMID 23384741.
270. Whitehead MI, Townsend PT, Gill DK, Collins WP, Campbell S (March 1980). "Absorption and metabolism of oral progesterone". British Medical Journal. 280 (6217): 825–827. doi:10.1136/bmj.280.6217.825. PMC 1600943. PMID 7370683.
271. Whitehead M, Lane G, Townsend P, Siddle N, Pryse-Davies J, King RJ (May 1981). "Oral progesterone". British Medical Journal. 282 (6274): 1476. doi:10.1136/bmj.282.6274.1476-a. PMC 1505208. PMID 6784875.
272. ^ Morville R, Dray F, Reynier J, Barrat J (1982). "" [The bioavailability of natural progesterone given by mouth. Measurement of steroid concentrations in plasma, endometrium and breast tissue]. Journal de Gynécologie, Obstétrique et Biologie de la Reproduction (in French). 11 (3): 355–363. PMID 7119381.
273. ^ Lane G, Siddle NC, Ryder TA, Pryse-Davies J, King RJ, Whitehead MI (October 1983). "Dose dependent effects of oral progesterone on the oestrogenised postmenopausal endometrium". British Medical Journal. 287 (6401): 1241–1245. doi:10.1136/bmj.287.6401.1241. PMC 1549751. PMID 6315123.
274. Adlercreutz H, Martin F (February 1980). "Biliary excretion and intestinal metabolism of progesterone and estrogens in man". Journal of Steroid Biochemistry. 13 (2): 231–244. doi:10.1016/0022-4731(80)90196-X. PMID 6991820. It is generally accepted that orally administered progesterone has little biological effect.
275. González ER (April 1981). "Even oral progesterone may be effective". JAMA. 245 (14): 1394. doi:10.1001/jama.1981.03310390003001. PMID 7193749.
276. Piette P (August 2018). "The history of natural progesterone, the never-ending story". Climacteric. 21 (4): 308–314. doi:10.1080/13697137.2018.1462792. PMID 29806794. S2CID 44066213.
277. Hargrove JT, Maxson WS, Wentz AC (October 1989). "Absorption of oral progesterone is influenced by vehicle and particle size". American Journal of Obstetrics and Gynecology. 161 (4): 948–951. doi:10.1016/0002-9378(89)90759-X. PMID 2801843.
278. "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations: 019781". Food and Drug Administration. 2 July 2010. Retrieved 7 July 2010.
279. "TherapeuticsMD Announces FDA Approval of TX-001HR: BIJUVA™ (Estradiol and Progesterone) Capsules for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause". Archived from the original on 5 May 2019. Retrieved 2 May 2019.
280. ^ Malik S, Krishnaprasad K (February 2016). "Natural Micronized Progesterone Sustained Release (SR) and Luteal Phase: Role Redefined!!". Journal of Clinical and Diagnostic Research. 10 (2): QE01–QE04. doi:10.7860/JCDR/2016/17278.7212. PMC 4800604. PMID 27042538.
281. ^ Kirk EP, Serat S, Burrows LJ, Mott LA, Yeo KJ, Fitzmaurice T, et al. (1997). "A pharmacokinetic study of micronized natural progesterone extended release tablets". Restore Health. Archived from the original on 4 March 2019.
282. Greenblatt RB (December 1954). "The physiologic effectiveness of progesterone vaginal suppositories". The Journal of Clinical Endocrinology and Metabolism. 14 (12): 1564–1567. doi:10.1210/jcem-14-12-1564. PMID 13211792.
283. ^ Benziger DP, Edelson J (1983). "Absorption from the vagina". Drug Metabolism Reviews. 14 (2): 137–168. doi:10.3109/03602538308991387. PMID 6301793.
284. "NEW Prescription Products". Journal of the American Pharmaceutical Association (Practical Pharmacy Ed.). 16 (3): 193–200. 1955. doi:10.1016/S0095-9561(16)33664-7. ISSN 0095-9561.
285. Hamburger C (1965). "Administration of Progesterone in the Form of Suppositories". Acta Endocrinologica. 49 (3_Suppl): S101. doi:10.1530/acta.0.049S101. ISSN 0804-4643.
286. Unlisted Drugs. Unlisted Drugs. 1976. p. 360.
287. The Belfast Gazette. H.M. Stationery Office. January 1977. p. 158.
288. Negwer M (1978). Organic-chemical Drugs and Their Synonyms. Akademie-Verlag. p. 872.
289. Racowsky C, Schlegel PN, Fauser BC, Carrell D (7 June 2011). Biennial Review of Infertility. Springer Science & Business Media. pp. 84–85. ISBN 978-1-4419-8456-2.
290. "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations: 020701". Food and Drug Administration. 2 July 2010. Retrieved 7 July 2010.
291. "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations: 022057". Food and Drug Administration. 2 July 2010. Retrieved 7 July 2010.
292. ^ Faundes A, Brache V, Alvarez F (2004). "Pros and Cons of Vaginal Rings for Contraceptive Hormone Delivery". American Journal of Drug Delivery. 2 (4): 241–250. doi:10.2165/00137696-200402040-00004. ISSN 1175-9038. S2CID 72093345.
293. Friend DR (October 2016). "Development of controlled release systems over the past 50years in the area of contraception". Journal of Controlled Release. 240: 235–241. doi:10.1016/j.jconrel.2015.12.043. PMID 26732558.
294. Rabe T (2007). "Contraception – Update and Trends" (PDF). J. Reproduktionsmed. Endokrinol. 4 (6): 337–357. ISSN 1810-2107.
295. Hillery AM, Park K (15 September 2016). Drug Delivery: Fundamentals and Applications, Second Edition. CRC Press. pp. 294–. ISBN 978-1-4822-1772-8.
296. ^ Rose S, Chaudhari A, Peterson CM (August 2009). "Mirena (Levonorgestrel intrauterine system): a successful novel drug delivery option in contraception". Advanced Drug Delivery Reviews. 61 (10): 808–812. doi:10.1016/j.addr.2009.04.022. PMID 19445984.
297. Journal de Gynécologie, Obstétrique et Biologie de la Reproduction. Masson: 198, 214, 327. 1972 https://books.google.com/books?id=NjH9dmzFBfsC. {{cite journal}}: Missing or empty |title= (help)
298. Sitruk-Ware R (January 1989). "Transdermal delivery of steroids". Contraception. 39 (1): 1–20. doi:10.1016/0010-7824(89)90012-7. PMID 2642780.
299. Potts RO, Lobo RA (May 2005). "Transdermal drug delivery: clinical considerations for the obstetrician-gynecologist". Obstetrics and Gynecology. 105 (5 Pt 1): 953–961. doi:10.1097/01.AOG.0000161958.70059.db. PMID 15863530. S2CID 23411589.
300. Unfer V, di Renzo GC, Gerli S, Casini ML (2006). "The Use of Progesterone in Clinical Practice: Evaluation of its Efficacy in Diverse Indications Using Different Routes of Administration". Current Drug Therapy. 1 (2): 211–219. doi:10.2174/157488506776930923.
301. Unfer V, Casini ML, Marelli G, Costabile L, Gerli S, Di Renzo GC (August 2005). "Different routes of progesterone administration and polycystic ovary syndrome: a review of the literature". Gynecological Endocrinology. 21 (2): 119–127. doi:10.1080/09513590500170049. PMID 16109599. S2CID 24890723.
302. Morton IK, Hall JM (31 October 1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 232–. ISBN 978-0-7514-0499-9.
303. Gelijns A (1991). Innovation in Clinical Practice: The Dynamics of Medical Technology Development. National Academies. pp. 195–. NAP:13513.
304. Purandare AC, Hajare A, Krishnaprasad K, Bhargava A (2014). "Prescription event monitoring study to assess the safety profile of oral natural micronized progesterone sustained release in India". International Journal of Medical Research & Health Sciences. 3 (4): 975. doi:10.5958/2319-5886.2014.00034.4. ISSN 2319-5886.
305. Haleem S, Khan MI (March 2015). "Changing Indian Market Trends of NMP: A Review". International Journal of Pharma Research & Review. 4 (3): 28–30.
306. Nigam A (2018). "Luteal Phase Support: Why, When and How" (PDF). Pan Asian Journal of Obstetrics & Gynecology. 1 (2): 79–83. Archived from the original (PDF) on 19 August 2020.
307. Malhotra J, Krishnaprasad K (January 2016). "Open-label, Prospective, Investigator Initiated Study to Assess the Clinical Role of Oral Natural or Synthetic Progesterone During Stimulated IUI Cycles for Unexplained Infertility". Journal of Clinical and Diagnostic Research. 10 (1): QC08–QC10. doi:10.7860/JCDR/2016/17058.7106. PMC 4740654. PMID 26894126.
308. Prabhat P, Korukonda K (2018). "A Drug Utilisation Surveillance Study to Assess the Clinical Utility and Safety of Oral Natural Micronized Progesterone SR in High Risk Pregnancies: NAP-DELAY Study". Journal of Clinical and Diagnostic Research. doi:10.7860/JCDR/2018/34886.12118. ISSN 2249-782X.
309. Singh N, Reddy A (April–June 2015). "Current Concepts in Management of Preterm Labour - A Review Article". Indian Obstetrics and Gynaecology. 5 (2). Archived from the original on 29 August 2021. Retrieved 19 August 2020.
310. "Estradiol/progesterone injection - Laboratorios Carnot". AdisInsight. Springer Nature Switzerland AG.
311. "Estradiol/progesterone - TherapeuticsMD". AdisInsight. Springer Nature Switzerland AG.
312. ^ Brotherton J (1976). Sex Hormone Pharmacology. Academic Press. pp. 341–342. ISBN 978-0-12-137250-7.
313. ^ Neumann F, Diallo FA, Hasan SH, Schenck B, Traore I (1976). "The influence of pharmaceutical compounds on male fertility". Andrologia. 8 (3): 203–235. doi:10.1111/j.1439-0272.1976.tb02137.x. PMID 793446. S2CID 24859886.
314. Sundsfjord JA, Aakvaag A, Norman N (August 1971). "Reduced plasma testosterone and LH in young men during progesterone administration". Journal of Reproduction and Fertility. 26 (2): 263–265. doi:10.1530/jrf.0.0260263. PMID 5558416.
315. Heller CG, Laidlaw WM, Harvey HT, Nelson WO (July 1958). "Effects of progestational compounds on the reproductive processes of the human male". Annals of the New York Academy of Sciences. 71 (5): 649–665. doi:10.1111/j.1749-6632.1958.tb54641.x. PMID 13583821. S2CID 32637425.
316. Heller CG, Moore DJ, Paulsen CA, Nelson WO, Laidlaw WM (December 1959). "Effects of progesterone and synthetic progestins on the reproductive physiology of normal men". Federation Proceedings. 18: 1057–1065. PMID 14400846.
317. ^ "Progesterone topical - Novavax". AdisInsight. Springer Nature Switzerland AG.
318. Plunkett JW (March 2004). Plunkett's Nanotechnology & MEMS Industry Almanac. Plunkett Research, Ltd. pp. 265–. ISBN 978-1-59392-004-3.
319. "Form 10-K Novavax, inc". ir.novavax.com. Archived from the original on 22 December 2019. Retrieved 15 January 2022.

Further reading

• Sitruk-Ware R, Bricaire C, De Lignieres B, Yaneva H, Mauvais-Jarvis P (October 1987). "Oral micronized progesterone. Bioavailability pharmacokinetics, pharmacological and therapeutic implications--a review". Contraception. 36 (4): 373–402. doi:10.1016/0010-7824(87)90088-6. PMID 3327648.
• Ruan X, Mueck AO (November 2014). "Systemic progesterone therapy--oral, vaginal, injections and even transdermal?". Maturitas. 79 (3): 248–255. doi:10.1016/j.maturitas.2014.07.009. PMID 25113944.